<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Redox Control of Microglial Function: Molecular Mechanisms and Functional Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Rojo, Ana I.; McBean, Gethin J.; Cindric, Marina; et al.</td>
</tr>
<tr>
<td><strong>Publication date</strong></td>
<td>2014-10-06</td>
</tr>
<tr>
<td><strong>Publication information</strong></td>
<td>Antioxidants and Redox Signaling, 21 (12): 1766-1801, PMID 24597893</td>
</tr>
<tr>
<td><strong>Publisher</strong></td>
<td>Mary Ann Liebert</td>
</tr>
<tr>
<td><strong>Item record/more information</strong></td>
<td><a href="http://hdl.handle.net/10197/6414">http://hdl.handle.net/10197/6414</a></td>
</tr>
<tr>
<td><strong>Publisher's statement</strong></td>
<td>Final publication is available from Mary Ann Liebert, Inc., publishers <a href="http://dx.doi.org/10.1089/ars.2013.5745">http://dx.doi.org/10.1089/ars.2013.5745</a></td>
</tr>
<tr>
<td><strong>Publisher's version (DOI)</strong></td>
<td><a href="http://dx.doi.org/10.1089/ars.2013.5745">http://dx.doi.org/10.1089/ars.2013.5745</a></td>
</tr>
</tbody>
</table>
Abstract

Neurodegenerative diseases are characterized by chronic microglial over-activation and oxidative stress. It is now beginning to be recognized that reactive oxygen species (ROS) produced by either microglia or the surrounding environment not only impact neurons but also modulate microglial activity. In this review, we first analyze the hallmarks of pro-inflammatory and anti-inflammatory phenotypes of microglia and their regulation by ROS. Then, we consider the production of reactive oxygen and nitrogen species by NADPH oxidases and nitric oxide synthases and the new findings that also indicate an essential role of glutathione (γ-glutamyl-l-cysteinylglycine) in redox homeostasis of microglia. The effect of oxidant modification of macromolecules on signaling is analyzed at the level of oxidized lipid by-products and sulfhydryl modification of microglial proteins. Redox signaling has a profound impact on two transcription factors that modulate microglial fate, nuclear factor kappa-light-chain-enhancer of activated B cells, and nuclear factor (erythroid-derived 2)-like 2, master regulators of the pro-inflammatory and antioxidant responses of microglia, respectively. The relevance of these proteins in the modulation of microglial activity and the interplay between them will be evaluated. Finally, the relevance of ROS in altering blood brain barrier permeability is discussed. Recent examples of the importance of these findings in the onset or progression of neurodegenerative diseases are also discussed. This review should provide a profound insight into the role of redox homeostasis in microglial activity and help in the identification of new promising targets to control neuroinflammation through redox control of the brain. Antioxid. Redox Signal. 21, 1766–1801.
I. Introduction

Thanks to the use of antibiotics and improved lifestyles, infectious diseases are no longer a primary cause of death in developed countries, and it is hoped that this situation will extend to the whole world before long. However, improved life expectancy has increased the prevalence of chronic diseases, including neurodegenerative diseases. Old and new maladies share a common immune response, but in chronic degenerative diseases the role of the innate immune system appears to be particularly relevant. In the central nervous system (CNS), the innate immune system is represented by a type of macrophage, known collectively as microglia, initially described by Ramón y Cajal and Pío del Río Hortega as a member of the reticulo-endothelial system at a time, during the 1920s, when it was believed that the brain was composed of three cellular elements: neurons, “neuroglia,” representing astroglia, and “the third element,” which was identified as microglia (67, 68).

Although present in all brain regions, microglia are mainly in the gray matter, achieving the highest concentration in hippocampus, olfactory telencephalon, basal ganglia, and substantia nigra, and they comprise 0.5–16% of total nerve cells (143).

During embryogenesis, microglia migrate into the brain parenchyma and retain a low turn-over rate (141), constituting what for many years was believed to be the only phagocytic cell population of the CNS. During development, they participate in the clearance of the huge quantity of neurons that are produced in large excess in the embryo and later die of apoptosis (278). Under normal healthy conditions, microglial cells continuously survey nerve tissue, monitor the integrity of synapses (328), fight infectious agents, and remove apoptotic and necrotic cells with subsequent suppression or promotion of neuroinflammation (84).

While microglia-driven neuroinflammation, undoubtedly, has a beneficial effect on scavenging cell debris, tissue healing, and repair, it is also becoming clear that chronic activation of this cell type leads to noxious effects on neurons and, thus, participates in the pathophysiology of neurodegenerative diseases (233). A key determinant of microglial neurotoxicity is the release of excitotoxins, including glutamate (14, 241), quinolinate (102), D-Serine (343), cyclooxygenase (COX)-derived prostaglandins (47), and, of particular relevance to this review, reactive oxygen species (ROS) and reactive nitrogen species (RNS). These molecules not only influence the surrounding environment but also modulate microglial dynamics between classical pro-inflammatory and alternative wound-healing phenotypes and participate in weakening of the blood–brain barrier (BBB) permeability, thereby facilitating the recruitment of peripheral immune cells at sites of inflammation.

Here, we will review our current knowledge on microglial regulation with a particular focus on the role of ROS. This review will illustrate the relevance of ROS not only as a part of microglial function but also as participants in a feed-forward mechanism of activation that may contribute to chronic unremitting inflammation in neurodegenerative diseases.

II. Microglial Profiles and the Influence of Redox Dynamics

A. Description of microglial phenotypes

Under physiological conditions, microglia display small cell bodies and thin processes that extend and branch several
Control NF-jB increasing the phosphorylation levels of the kinases that ties. During this phase, ROS/RNS act as second messengers that are capable of modulating the M1 gene profile. However, other transcription factors, including NRF2, are increased in response to ROS/RNS but probably in a retarded fashion. NRF2 will restore redox homeostasis and attenuate M1 in favor of M2 phenotypes. NF-jB, nuclear factor kappa-light-chain-enhancer of activated B cells; NOS, nitric oxide synthase; NOX, NADPH oxidase; NRF2, nuclear factor (erythroid-derived 2)-like 2; RNS, reactive nitrogen species; ROS, reactive oxygen species.

The role of nitric oxide (NO) released by inducible isoform of nitric oxide synthase (iNOS) in the acquisition of M1 phenotype is not so clear. iNOS is not expressed at a relevant level in microglia in situ in the brain but can be induced in astrocytes at least in the rodent brain and only cultured microglia express iNOS. With regard to prostaglandins, COX1 is expressed in microglia and COX2 is expressed in neurons. All of these events help defend the tissue from acute injuries caused by external or internal agents. Thus, M1 microglia are generally considered potent effector cells that kill and engulf micro-organisms as well as tumor or otherwise damaged cells. This response is rapidly reinforced by cytokine factors, including ROS and RNS, released by microglia themselves and by surrounding cells.

FIG. 1. Microglial phenotypes are tightly controlled by ROS/RNS levels. Under surveillance mode, microglial cells exhibit low levels of ROS/RNS that might be properly managed by the antioxidant machinery. After an inflammatory challenge, microglial cells execute an M1 program that is characterized by a rapid and high increase in ROS/RNS levels mainly derived from the NOX and NOS activities. During this phase, ROS/RNS act as second messengers increasing the phosphorylation levels of the kinases that control NF-jB to further up-regulate the pro-inflammatory M1 gene profile. However, other transcription factors, including NRF2, are increased in response to ROS/RNS but probably in a retarded fashion. NRF2 will restore redox homeostasis and attenuate M1 in favor of M2 phenotypes. NF-jB, nuclear factor kappa-light-chain-enhancer of activated B cells; NOS, nitric oxide synthase; NOX, NADPH oxidase; NRF2, nuclear factor (erythroid-derived 2)-like 2; RNS, reactive nitrogen species; ROS, reactive oxygen species.

B. The microglial M1/M2 balance is modulated by the redox status

Redox homeostasis influences the acquisition of the final microglial phenotype by a variety of mechanisms. During M1 execution, the normally low levels of ROS/RNS associated with surveillance microglia are dramatically elevated, due to activation of NADPH oxidase (NOX) and nitric oxide synthase (NOS) enzymes (250). Under these conditions, ROS/RNS act as second messengers that are capable of modulating gene expression by inducing signaling kinases or inhibiting signaling phosphatases (327, 373). As we will describe next, transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-jB) is particularly sensitive to ROS and is central to acquisition of the pro-inflammatory M1 polarization. In contrast, signaling cascades involved in M2 acquisition are less well understood, yet cytokines such as IL-4 that signal via STAT3 and STAT6 appear to be important (27, 272, 285). Considering that ROS/RNS should be lowered after the initial pro-inflammatory response to prevent further tissue damage, it is reasonable to
suggest that induction of anti-oxidant and cytoprotective genes will be a signature of M2 polarization and indeed, as will be discussed later, novel findings indicate that the transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2), master regulator of redox homeostasis, favors an M2 compared with an M1 phenotype.

The connection between microglial plasticity and redox state has been analyzed in a range of experimental models. For instance, Rossi-George et al. showed that Cu(I) has the capacity to shift LPS-activated M1-microglia toward an M2 phenotype, but only in the presence of NO (264). Data from in vivo models have established that redox homeostasis of microglia depends mainly on NOX activity. Accordingly, Choi et al. (48) showed that pharmacological inhibition of NOX, or genetic deletion of its functional p47phox subunit, changed microglia from an M1 to M2 phenotype. The authors observed that the microglial marker IBA-1 was significantly reduced in hippocampus from p47phox -/- mice along with a significant reduction of pro-inflammatory factors such as TNF, CCL2, and CCR2. In contrast, IL-4 and IL-4Rz messenger RNA levels were elevated after an LPS injection in p47phox -/- mice compared with wild-type littermates. In addition, expression of the genes encoding Ym1 and FIZZ1 exhibited a marked induction in p47phox -/- mice compared with wild type. Moreover, in the 6-hydroxydopamine (6-OHDA)-induced Parkinson’s disease (PD) mouse model, Hernandez et al. (100) recently described that mice lacking the catalytic subunit of NOX2, gp91phox -/- are completely protected against glial M1 over-activation, as determined by reduced release of IL-1, interferon-γ (IFN-γ), and TNF.

Evidence for a role of NRF2 in the modulation of microglial dynamics between M1 and M2 phenotypes was reported by Cuadrado’s group in the context of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism (116, 262). Compared with wild-type littermates, NRF2-deficient mice exhibited increased levels of pro-inflammatory M1 markers (COX-2, iNOS, IL-6, and TNF) and reduced levels of alternative M2 markers (FIZZ-1, YM-1, ARG1, and IL-4) in response to this neurotoxin.

Suppressors of cytokine signaling (SOCS) are a group of inducible proteins that prevent neuroinflammation by inducing feedback inhibition of cytokine signaling at the level of the JAK/STAT axis (12). The SOCS family includes eight members (cytokine-inducible SH2 protein, CIS, and SOCS1-7) that orchestrate distinct reactions by antagonizing STAT activation. They bind to phosphorylated tyrosine residues on cytokine receptors and to the SH2 domain of JAKs. This physical interaction switches off JAKs by acting as pseudo-substrates and recruiting the ubiquitination machinery via the SOCS-box domain (350). At least SOCS1 and SOCS3 are expressed in microglia. SOCS1 is induced by various cytokines, including IFN-γ, IL-4, and TNF, and down-regulates the signals induced by these cytokines, mainly IFN-γ, in a feedback loop. SOCS3 inhibits signaling by the IL-6 family of cytokines and mediates the anti-inflammatory effects of IL-10. It has been reported that an additional mechanism of

### Table 1. Characteristic Antigens of the Microglial Phenotypes

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Cytokines/chemokines</th>
<th>Receptors</th>
<th>Enzymes</th>
<th>Other markers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surveilling</td>
<td>Low</td>
<td>CXCR2</td>
<td>Low iNOS</td>
<td>low ARG1</td>
</tr>
<tr>
<td>M1-profile</td>
<td>IL-6</td>
<td>CD172a</td>
<td>CD200R1</td>
<td>Low IBA-1</td>
</tr>
<tr>
<td></td>
<td>IL-1</td>
<td>CD172a</td>
<td>CD200R1</td>
<td>Low F4/80</td>
</tr>
<tr>
<td></td>
<td>IL-12p40</td>
<td>C-type lectins</td>
<td>iNOS</td>
<td>COX1</td>
</tr>
<tr>
<td></td>
<td>TNF</td>
<td>CAT2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IFN</td>
<td>CD8</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>F4/80</td>
<td>ARG1</td>
<td>YM-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IBA-1</td>
<td>Lack of iNOS</td>
<td>FIZZ1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MARCO</td>
<td>sphk1/2</td>
<td>SOCS3</td>
</tr>
<tr>
<td>M2-profile</td>
<td>IL-4</td>
<td>MHCIIR</td>
<td>ARG1</td>
<td>YM-1</td>
</tr>
<tr>
<td></td>
<td>IL-5</td>
<td>C-type lectins</td>
<td>Lack of iNOS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IL-13</td>
<td>CAT2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IL-10</td>
<td>MR</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TGF</td>
<td>DC-SIGN</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CCL-18</td>
<td>IL-4Rz</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL-1Rz</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CD36</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CD136</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ARG1 arginase 1; CAT2, cationic amino-acid transporter 2; CCL-18, chemokine 18; CD172a, receptor for CD47; CD200R1, receptor for CD200; CXCR2, receptor for CX3-chemokine ligand-1; DC-SIGN, dendritic cell-specific intracellular adhesion molecule 3-grabbing integrin; FIZZ1, found in inflammatory zone; IBA-1, ionized calcium-binding adapter molecule 1; IFN, interferon; IL-1, interleukin 1; IL-1Ra, interleukin 1 receptor antagonist; IL-4R, interleukin 4 receptor α; IL-5, interleukin 5; IL-6, interleukin 6; IL-10, interleukin 10; IL-12p40, interleukin 12 p40 subunit; IL-13, interleukin 13; iNOS, inducible nitric oxide synthase; MARCO, macrophage receptor with collagenous structure; MHCIIR, major histocompatibility antigen II; MR, manose receptor; RAGE, receptor for advanced glycation endproducts; SOCS3, suppressor of cytokine signaling 3; sphk, sphingosine kinase; TGF-β, tumor growth factor b; TNF, tumor necrosis factor; YM-1, mouse homolog chitinase 3 like 1 (CHI3L1).
up-regulation of SOCS expression is the response to ROS/RNS and the fact that they repress the M1 program (249). Thus, the protein levels of SOCS1 and SOCS3 are drastically elevated in response not only to TNF but also to hydrogen peroxide (H$_2$O$_2$) in Jurkat T cells and mouse splenocytes (218). With regard to microglia, electrophilic compounds such as a caffeamide derivative (163) and gemfibrozil (89) have been reported to exert anti-neuroinflammatory functions through induction of SOCS3. The role of SOCS in neuroinflammation has been studied mainly in the context of multiple sclerosis (MS) where they are proposed to be putative targets to modulate chronic inflammation (78).

It has been suggested that M1 and M2 phenotypes are mutually independent. Thus, anti-inflammatory cytokines IL-4 or IL-13 prevent the induction of pro-inflammatory mediators such as iNOS, COX-2, IL-6, and TNF (52, 165, 244). In the mouse model of amyotrophic lateral sclerosis (ALS), based on the expression of mutant Cu/Zn-superoxide dismutase (SOD1), microglia isolated from animals in their early stage of disease exhibit an M2 phenotype that is protective to motoneurons; whereas microglia isolated from end-stage mice have adopted an M1 phenotype with exacerbated NOX2 activity, supporting the dual phenotypes of microglia and their transformation during progression of neurodegenerative diseases (154). Aging is associated with a progressive increase in ROS, and, therefore, it is possible that those changes might be due, in part, to ROS-mediated reinforcement of the M1 program.

The protein lipocalin 2 (LCN2) is secreted by astroglia and microglia under pro-inflammatory conditions (147, 148) and elevated ROS levels (294) and strengthens the expression of M1-markers (IL-12, IL-23, iNOS, TNF, and CXCL10) without affecting M2-markers. LCN2 plays a central role in iron transport and prevents oxidant Fenton reactions, as LCN2-deficient mice exhibit elevated intracellular labile iron and exacerbated sensitivity to endotoxin (292). In contrast to wild-type microglia, cells from LCN2-deficient mice failed to induce M1-markers in response to combined LPS plus IFN-γ treatment. However, their capacity to induce M2 markers in response to IL-4 was increased. LCN2 inhibited phosphorylation of STAT6 in IL-4-stimulated microglia, suggesting that LCN2 acts as a brake for the M2 program.

The differential expression of iNOS and ARG1 in M1 compared with M2 profiles provides an attractive model for the molecular basis of redox control of microglial phenotypes (Fig. 2). Both enzymes use l-arginine as a substrate, but iNOS produces NO, favouring nitrosative and oxidative stress and the M1 phenotype, whereas ARG1 generates ornithine. Ornithine aminotransferase generates glutamate, proline, and hydroxyproline. Hydroxyproline is an essential component of collagen synthesis and, therefore, contributes to maintenance of the ECM, reinforcing the M2 program. In this program, l-Arginine is transformed to ornithine by ARG1, because (i) ARG1 is highly expressed; (ii) iNOS expression is silenced, in part, due to the actions of IL-4 and IL-13; and (iii) although iNOS is catalytically more effective than ARG1 (K$_m$inO$_2$ = 3–10 μM; K$_m$ARG1 = 3–10 mM), the V$_{max}$ of ARG1 is 1500-fold greater (52). In the M1-program, the expression of each enzyme is reversed, enabling high NO generation through iNOS activity.

The importance of oxidative stress in M1/M2 polarization goes beyond the acquisition of either phenotype and may participate in the development of endotoxin tolerance (ET). In ET, the exposure of an organism to an inflammatory stimulus (for example, the endotoxin LPS as a “first hit”) results in a low immune response to a subsequent inflammatory insult (“second hit”). The pathological consequence is an impaired capacity to respond to new infections. Although ET is best characterized in the acute inflammatory reactions of sepsis, we speculate that it may be a general adaptive mechanism that could affect chronic diseases in which prolonged low-grade inflammation might act as the first hit. Taking Alzheimer’s disease (AD) as a model, clinical observations indicate that these patients show a greater susceptibility to infections compared with age-matched healthy individuals (24). Considering that the BBB is weakened in AD, enabling bidirectional transit of molecules, and that both neurons and glia release several modulators of inflammation, it is plausible that low-grade chronic neuroinflammation in AD might result in a state of reduced immunological response or “tolerance” to peripheral infections. Systems analyses have demonstrated that activation of transcription factor ATF3 is an early response to endotoxin in macrophages, which represses the production of IL-6, TNF, and IFN-γ (105). Since ROS deplete the levels of the tripeptide glutathione (γ-glutamyl-l-cysteinylglycine) (GSH), and GSH depletion enhances endotoxin-induced ATF3 expression, it follows that oxidative stress will also modulate ET. In fact, ROS-mediated induction of ATF3 caused increased susceptibility to bacterial and fungal infections through the suppression of IL-6 in wild-type but not in Atf3-knock-out mice (105). Pena et al., (232), who also used a systems biology approach and bioinformatics analysis, determined that gene and protein expression during ET is similar to that found during M2 polarization. While these observations point to redox control as a crucial element in the development of ET, it is not yet clear how this impacts microglia and brain tolerance to either acute infections or progressive neurodegeneration. In fact, experimental evidence suggests that innate immune cells in the brain do not become tolerant to repeated
systemic administration of LPS, but, on the contrary, lead to prolonged and damaging cytokine production which may have a profound effect on the onset or progression of pre-existing neurodegenerative disease (248).

C. Brain aging and neurodegenerative diseases alter microglial dynamics and the cross-talk between neurons and microglia

There is a strong correlation between brain aging and neurodegeneration and redox imbalance, as well as low-grade chronic inflammation. One would predict that, over time, microglia would become increasingly susceptible to accumulative oxidative damage, due to their limited capacity to divide (4, 90, 192) and to the need to remove copious amounts of ROS/RNS after M1 activation. Consistently, microglia from old or degenerated brains undergo morphological changes that resemble the M1 phenotype, with decreased branching and beading of their processes (295, 296). In addition, these microglial cells present a hyper-inflammatory response (294) with increased M1-markers (MHCI, CD86, CD68, TLRs, and pro-inflammatory cytokines such as IL-1, TNF, IL-6, and CD11) and a parallel decrease in anti-inflammatory mediators (IL-10, BDNF, inhibitor of NF-kB [IκB] inhibitor, and MAD3A) [reviewed in refs. (83, 215)].

As will be discussed later, GSH is a major low-molecular-weight antioxidant that is used for the maintenance of microglial redox balance, and its levels decrease with aging. For example, the brain of aged rodents exhibits a decrease in GSH accompanied with higher glutathione disulfide (GSSG) levels compared with young animals (258). Microglia from aged mice constitutively secrete more TNF and IL-6 relative to microglia from young mice and are less responsive to stimulation (213). Furthermore, microglia from aged mice have lower GSH levels and internalise less amyloid beta (Aβ) peptide than young mice. It has long been recognized that there is an age-related increase in activities of GSH-consuming enzymes, including glutathione peroxidase (GPx), glutathione S-transferase (GST), and γ-glutamyl transpeptidase (γGT) in rat brain (110). Similarly, in AD patients, up-regulation of a specific isoform of GST (hGST3) has been reported (306). On the other hand, γ-GluCys ligase expression and activity has been widely reported to decline with age (157, 352, 374), thus contributing to a failure of cells to maintain adequate GSH levels for anti-oxidant protection.

An essential aspect of normal brain function is the bidirectional communication between neurons and neighboring glia, including microglia. With regard to the role of ROS in this review, it will be implicit that activated microglia may release several factors, including superoxide anion (O2•−) and H2O2, that impact the surrounding brain parenchyma damaging neurons and leading to a vicious cycle of microglial activation and neuron damage. With regard to signaling from neurons to microglia, recent studies are uncovering a mechanism used by the neurons to shut down microglial over-activation. Several groups have shown that the chemokine fractalkine (CX3CL1) is released by injured neurons and interacts with its cognate receptor, which in the brain is exclusively expressed in microglia. Cuadrado’s group (142) has reported that CX3CL1 released by TAU-injured neurons up-regulates in microglia the transcription factor NRF2, which as will be discussed later, is a master regulator of redox homeostasis. By this mechanism, neurons limit the extent of ROS release and, thus, prevent over-activation of microglia.

III. Sources of ROS in Microglia: NOX and NOS Enzymes

As with any other aerobic eukaryotic cells, incomplete reduction of molecular oxygen in mitochondrial respiration in microglia leads to generation of the O2•−. Despite the marvelous design of complex IV of the mitochondrial respiratory chain, which is admirably suited to quench O2 until it is fully reduced to water, it is estimated that 1–2% of molecular oxygen generates O2•− (30). While O2•− is not a very reactive molecule, it undergoes spontaneous or enzymatic dismutation by Mn-SOD (SOD2) in mitochondria and generates H2O2, which is arguably the most important ROS signaling molecule. One potential effect of O2•− in the microglia is the release of Fe3+-from 4Fe-4S clusters of complex I and complex II, leading, on the one hand, to loss of energy production and, on the other, to the generation of the very reactive hydroxyl radical (·OH) by the Fenton reaction (246). ROS production by microglia is a part of their physiological function. While this source of ROS generation is not specific to microglia, it may be relevant to microglial function, particularly during the aging process as discussed earlier. In addition to mitochondrial respiration, ROS production by NOX in microglia occurs mainly at the plasma membrane, as discussed in the next section.

A. NOX system

The main source of ROS in microglia is the activation of NOX (28). Earlier investigations demonstrated a relevant role of NOX in the acute inflammatory response by neutrophils, participating in a respiratory burst that is aimed at killing pathogens (66, 238). Later studies demonstrated that monocytes/macrophages, including microglia, also express NOX, and it is now accepted that NOX activity is found in both phagocytic and non-phagocytic cells, such as astroglia and neurons (49, 251). Therefore, in addition to a role in pathogen defence, NOX participate in multiple cellular processes such as host defence, migration, changes in morphology of microglia, pro-inflammatory gene expression (251), up-regulation of different markers in response to inflammatory stimuli, and microglia-induced neurotoxicity (265). An excellent review on the role of NOX enzymes in the CNS has been recently published (207) and here, we will only provide a brief description of this system.

NOX is a multi-subunit enzyme complex that transfers electrons from NADPH and, to a lesser extent, NADH (23) to molecular oxygen, resulting in the formation of O2•− anion as the primary product, but in some NOX isoforms such as Nox4, O2•− dismutation is so fast that H2O2 is the end product detected (212, 281). Under resting conditions, the different subunits of this complex are localized in the cytosol (p40phox, p47phox, and p67phox) and in the cell membrane (cytochrome b558, comprising p22phox and gp91phox) and on stimulation, the catalytically active complex is assembled in the plasma membrane (5, 207).

Seven different NOX isoforms exist in humans: NOX1, NOX2 (also known as gp91phox), NOX3, NOX4, NOX5, dual oxygenase (DUOX)1, and DUOX2, which differ in subcellular localization and regulatory mechanisms (23, 207). Microglia
express at least NOX1, NOX2, and NOX4 isoforms, but most studies have focused on NOX2 (291). NOX2 levels are very low at the surveillance state and increase in the M1 state in both humans (86) and mice (341).

Although ROS generated by NOX in microglia will act on surrounding cells, in the context of this review, it is particularly relevant that their main target is the microglial cell itself, due to the proximity of their site of formation and their high degree of reactivity. This autocrine effect has received little attention, despite the fact that it will have a profound effect on microglial activity. For instance, increased expression of NOX4 leads to constitutive release of IL-6 and ROS generation in these cells (151). Therefore, NOX activation and subsequent ROS generation play a critical role in the regulation of microglial fate, including cell proliferation, induction of apoptosis during the embryonic phase, release of neurotransmitters, and pro-inflammatory cytokine production (99, 117, 179). This pro-inflammatory M1 response may play a key role in the pathological over-activation of microglia that has been reported in several neurodegenerative diseases.

Thus, NOX2-deficient mice that over-express the Swedish mutation of APP(Tg2576) exhibited a significant reduction in oxidative stress and behavioral deficits (228, 229), while the accumulation of Aβ fragments was not affected. In line with these observations, the inhibition of NOX2 with the peptide gp91ds-tat attenuates oxidative stress and behavioral deficits in mice over-expressing APP (229). Based on these preclinical studies, the inhibition of NOX2 could be considered a potential target to develop new drugs for the treatment of AD.

With regard to PD, a pathological examination of substantia nigra samples from patients and animal models has also revealed an up-regulation of microglial NOX2 (342). Thus, aggregated α-synuclein stimulates microglial ROS production via NOX2 activation and may cause the death of dopaminergic neurons (364). Indeed, in the toxic models of PD such as exposure to MPTP, the deletion of NOX2 caused a marked reduction of dopaminergic neuronal death (365), further evidencing the participation of microglial NOX2.

In ALS, an augmented expression of microglial NOX2 has been reported in patients with the SOD1 mutation (SOD1<sup>h93A</sup>) (177, 341) and in patients with sporadic form of the disease (341). The relevance of NOX2 in ALS pathogenesis was suggested by Marden et al. (177), who showed that homozygous knockouts of NOX1 and NOX2 significantly increased lifespan of the hybrid B6SJL transgenic SOD<sup>h93A</sup> mice. The greatest increase in survival was achieved in the NOX2 knockout (almost 100 days) compared with NOX1 knockout (around 33 days), indicating that NOX2 plays a predominant role. The extension of survival in the ALS SOD<sup>h93A</sup> mouse on NOX disruption was also reported by Harraz et al. (98). However, results from Wu et al. (341) showed that NOX2 deletion in the ALS mice only increases survival to 15 days. It is obvious that further characterization of the role of NOX2 in ALS is still required.

### B. NOS enzymes

Another hallmark of microglial over-activation is the high production of NO, but it should be emphasized that NO production is much more relevant in rodents than in humans. In fact, NOS activation is one of the distinctive characteristics in the inflammatory response between these two species, and this difference has been frequently underestimated at the time of extrapolating results from rodent models to human diseases.

At low concentrations, NO plays a significant role in several aspects of CNS physiology, including neurotransmission, vasodilation, cognition, sleep, appetite, body temperature, and neurosecretion (38, 170). Microglial NO is mainly synthesized from L-Arginine by the iNOS. iNOS functions independently of a rise in intracellular Ca<sup>2+</sup> unlike the other two constitutive NOS isoenzymes (endothelial NOS [eNOS] and neuronal NOS [nNOS]) and is transcriptionally induced by inflammatory mediators such as LPS and pro-inflammatory cytokines. Once induced, iNOS continuously produces high levels of NO that may cause neuronal death by mechanisms such as inhibition of mitochondrial cytochrome oxidase in neurons (31), inhibition of mitochondrial respiratory function, and release of exocytotoxic concentrations of glutamate via the N-methyl-D-aspartate receptor (293). Another important factor for NOS-mediated ROS production is the availability of its cofactor tetrahydrobiopterin (BH4). nNOS and eNOS can form dimers in the absence of BH4 (324), whereas iNOS dimerization requires the presence of BH4 (11). In NOS catalysis, BH4 controls coupling of the heme-oxygen intermediate with L-Arginine oxidation, thus controlling the generation of either NO or superoxide (187). When BH4 levels become deficient, the main product of NOS enzymes becomes O<sub>2</sub>·⁻, produced from the oxygenase domain of the enzyme. Therefore, the lack of BH4 converts iNOS into an O<sub>2</sub>·⁻-producing enzyme, altering the redox balance and leading to neuronal injury and more neuroinflammation.

Microglial iNOS can be regulated at transcriptional and post-transcriptional levels but as an inducible gene, it is mainly regulated at the transcriptional level. The most important transcription factor involved in iNOS expression is the NF-κB heterodimer p50:p65. All known inducers of iNOS have been shown to recruit NF-κB via one or more kinase pathways, such as tyrosine kinases (JAK, SRC family), MAPKK, protein kinase A (PKA), phosphatidyl inositol-3 kinase (PI3K), and protein kinase C (PKC) (269). In addition to these pathways, iNOS expression is also regulated by intracellular ROS production (269).

### C. Cross-talk between RNS and ROS

ROS derived from NOX act as second messengers to induce NO production. In this regard, microglial cells treated with antioxidant compounds such as N-acetylcysteine, pyrroline dithiocarbamate, and lycopene reduced their NO content (221, 225). In addition, iNOS activation in response to LPS/IFN-γ or Aβ is prevented by over-expression of either a non-active p47<sup>phox</sup> or a mutant RAC1 subunit of NOX, respectively (53, 231). Min et al. (193) showed that ganglioside induces the activation of microglia and the production of pro-inflammatory cytokines (IL-1β, TNF), and iNOS was attenuated by the inhibition of NOX system with diphenylene iodonium. Furthermore, Mander and Brown (174) showed that neurodegeneration induced by different pro-inflammatory stimuli, such as TNF, IL-1β, LPS, ATP, or phorbol 12-myristate 13-acetate, is mediated by dual activation of iNOS and NOX. In fact, synergic activation of NOX and NOS in microglia resulted in neuronal apoptosis that was prevented using scavengers of O<sub>2</sub>·⁻ anion or peroxynitrite (ONOO⁻).
At a high concentration, NO actively unbalances redox homeostasis due to its reactivity with ROS. NO can react with molecular oxygen and form nitrogen trioxide ($\text{N}_2\text{O}_3$) that not only efficiently nitrosylates thiol and amines, but also combines with $\text{O}_2^-$ to generate ONOO$^-$ that rapidly reacts with $\text{CO}_2$, producing nitrogen dioxide ($\text{NO}_2$) and carbonate ($\text{CO}_3^-$) which are also responsible for NO-related cytotoxicity. Figure 3 depicts the main ROS and RNS and how they modify several macromolecules. A more detailed description of their impact on lipid modification will be described later (Fig. 7).

Although the required levels of NO may be rather high to achieve neuronal cell death, an alternative mechanism would be for NO to react with $\text{O}_2^-$ generated via NOX and produce ONOO$^-$, which is potentially more neurotoxic than NO or $\text{O}_2^-$ alone (13, 21). As an example, the study by Wang and co-workers showed that in iNOS-deficient mice, Aβ did not inhibit long-term potentiation (LTP). Moreover, a NOX inhibitor prevented Aβ-mediated inhibition of LTP (365). Therefore, the interplay between iNOS and NOX to produce $\text{O}_2^-$, NO, and ONOO$^-$ seems to be essential in neurodegeneration.

IV. Glutathione and Microglial Redox Regulation

Despite its high dependence on oxidative metabolism, the brain has low levels of antioxidants and is vulnerable to oxidative stress. The activities of catalase, SOD, and GPX are modest in comparison to the liver and kidney (40, 300). GSH is the main low-molecular-weight antioxidant, and it has a crucial role in maintaining redox balance, particularly in astrocytes and microglia. The cytosolic concentration of GSH is typically in the low micromolar range with the majority (>90% in microglia) in the reduced (GSH) form. In culture, microglia maintain a higher concentration of GSH than either astrocytes or neurones (43, 104, 106), which underlies their considerable resistance to oxidative stress. As a strong reducing agent, GSH contributes in several ways to antioxidant defence: (i) rapid non-enzymatic clearance of NO and $\text{O}_2^-$, which is coupled to oxidation of GSH to GSSG (Fig. 4A); (ii) as an electron donor in Gpx-coupled reduction of $\text{H}_2\text{O}_2$ and ONOO$^-$ (Fig. 4B). The expression and activity of Gpx is higher in human and rat microglia than in neurones or astrocytes (104, 155, 247) and increases in response to oxidative stress. For example, the generation of oxygen-derived radicals after quinolinic acid-induced damage promotes expression of Gpx (155). (iii) GSH participates in regeneration of the reduced form of $\text{x}$-tocopherol (vitamin E) (42) and (iv) acts as a co-factor in a number of cellular isomerization reactions (267). (v) GSH functions as both a transport and storage form of the amino acid cysteine.

A. Glutathione metabolism

Synthesis of GSH takes place in the cytosol by two consecutive ATP-requiring reactions that form the first steps of the $\gamma$-glutamyl cycle, as illustrated in Figure 5. Loss of glutathione occurs as a result of its participation in redox or conjugation reactions, or due to export from the cell. During the Gpx-catalyzed detoxification of ROS, GSH is oxidized to GSSG and is recycled back to GSH by glutathione reductase (GR), an enzyme that is highly expressed in microglia (104). GSH synthesis is controlled by feedback inhibition of $\gamma$-glutamylcysteine synthetase ($\gamma$-GCL) by GSH and by availability of cysteine. As shown in Figure 5, cysteine is imported into microglia in its oxidized form, cystine, from the extracellular space using the plasma membrane Xc$^{-}$ cystine-glutamate exchanger. This is a two-subunit protein that operates as a sodium-independent, chloride-dependent electro-neutral antipporter, releasing glutamate in exchange for cystine in a 1:1 ratio (19, 184, 273). Glutamate released via the exchanger is recycled into microglia via high-affinity glutamate transporters [excitatory amino acid transporters (EAATs)], which is critical for avoiding the accumulation of extracellular glutamate that would pose a threat to neuronal survival (Fig. 6). Furthermore, glutamate uptake is necessary for providing the driving force to import more cystine via the
exchanger. The capacity of microglia to uptake glutamate is ~10% that of astrocytes, but its value is closely coupled to GSH production (234, 235).

B. Cystine-glutamate exchanger (Xc⁻) and glutamate homeostasis in microglia

Pro-inflammatory M1 activation of microglia causes up-regulation of the Xc⁻ exchanger (240) through increased expression of its catalytic subunit (223). The glutamate transporter 1 (GLT-1) subtype of high-affinity glutamate transporters is similarly up-regulated, and it mediates a higher intracellular glutamate level to drive cystine import and GSH synthesis (234, 368). However, the rate of high-affinity uptake of glutamate in activated microglia never matches that of astrocytes and, curiously, astrocytic glutamate uptake is inhibited after microglial activation (368) (Fig. 6). Consequently, M1 microglia actively promote neuronal degeneration through failure of high-affinity glutamate uptake systems and remove extracellular glutamate effectively. The situation is exacerbated by enhanced release of glutamate from M1 microglia due to up-regulation of the Xc⁻ exchanger (14, 15, 126, 368). Macrophage/microglial cells from patients with MS and mice with experimental autoimmune encephalomyelitis (EAE) have higher xCT (subunit of the Xc⁻ exchanger) expression than controls (223) and

![Diagram of the γ-glutamyl cycle](image)

**FIG. 5.** The γ-glutamyl cycle. Cystine enters the cytosol via the Xc⁻ cystine-glutamate exchanger (1) and is reduced to cysteine. Glutamate cysteine ligase catalyzes the formation of γ-glutamyl cysteine (2), and GSH is formed by the addition of glycine by glutathione synthase (3). After the export of GSH, γGT catalyzes transfer of the γ-glutamyl moiety to an acceptor amino acid (4), which is transferred to the cytosol and recycled via 5-oxoproline to glutamate (5). Cysteinylglycine is hydrolyzed by a DP that liberates cysteine and glycine (6). GSSG: oxidized form of GSH. DP, dipeptidase; GSSG, glutathione disulfide; γGT, γ-glutamyl transpeptidase.

![Diagram of microglial activation](image)

**FIG. 6.** Impact of microglial activation on extracellular glutamate. Under physiological conditions, microglia accumulate cystine (CySS), via the Xc⁻ cystine-glutamate exchanger, that is reduced to cysteine (Cys), the rate-limiting precursor for GSH synthesis. Glutamate released by the exchanger is taken up by high-affinity glutamate transporters on astrocytes. Activation of microglia by LPS acting through TLR4 causes up-regulation of the Xc⁻ exchanger and increased release of glutamate. Simultaneously, activated cells release ROS and pro-inflammatory cytokines that block high-affinity glutamate transporters, leading to activation of neuronal glutamate receptors and risk of cell death by excitotoxic mechanisms. LPS, lipopolysaccharide; TLR, toll-like receptor.
FIG. 7. Oxidized lipid by-products formed and detected during chronic neuroinflammatory diseases. During acute neuroinflammation, \( \text{O}_2^- \) is formed through the microglial NOX system. As inflammation progresses to the chronic state, iNOS produces nitric oxide. Since these two inflammatory phases can coexist, ONOO\(^-\) is formed in a reaction of \( \text{O}_2^- \) and NO radical. ONOO\(^-\) can react with carbon dioxide, thus forming highly reactive radicals (nitric dioxide radical, hydroxyl radical, and carbonate radical). Each of them has the ability to initiate lipid peroxidation. As a result, aldehydes—such as HNE, ACR, and MDA—are formed. During the oxidation of AA and DHA, isoprostanates and neuroprostanates are formed. However, IsoPs and NeuroPs are detected only in mild cognitive impairment and AD, ACR, MDA, and HNE are formed. The GSH pool plays a critical role in chronic inflammation linked to neurodegenerative diseases and, thus, represents a potential target for treatment. This view arises from the results of numerous studies in which the depletion of brain GSH has been recorded using N9 microglia, although it was noted that mitochondrial GSH was unaffected by the drop in total GSH after LPS/IFN-\( \gamma \) treatment (266). Recent evidence shows that several flavonoid extracts from Rhus verniciflua were effective in preventing glutamate-mediated toxicity and oxidative stress in microglial cells in vitro (46).

C. Microglial phenotypes and the glutathione pool

Several studies report that microglial activation alters the GSH pool, although the response differs among cell lines. For instance, LPS/IFN-\( \gamma \)-induced activation of iNOS in both enriched primary microglial cultures and the N11 microglial cell line elicits a 40% decrease in GSH that can be blocked by the inhibition of iNOS (44, 200, 214). Similar observations have been recorded using N9 microglia, although it was noted that mitochondrial GSH was unaffected by the drop in total GSH after LPS/IFN-\( \gamma \) treatment (266). However, in BV2 microglial cells, the depletion in GSH in response to LPS/IFN-\( \gamma \) was independent of NO production (200). Furthermore, two independent studies have shown that TNF treatment of primary microglial cells in culture produced a significant increase in GSH that was accompanied by a significant reduction in ROS levels (75, 235). The opposite occurred in oligodendrocytes, and it was concluded that signals from TNF induce an antioxidant response in microglia which is absent in oligodendrocytes.

There are several instances in which changes in the GSH pool alter the extent of microglial activation. Thus, depletion of GSH in human microglial cells with the \( \gamma \)-GCL inhibitor buthionine-S-sulfoximine (BSO) induces oxidative stress and an inflammatory response that causes the cells to secrete TNF, IL-6, and nitrite ions which are toxic to neuroblastoma SH-SYSY cells (145). A similar response occurs in astrocytes, which in both cell types is linked to calcium influx through TRPM2 channels. As expected, the stimulation of GSH synthesis in microglia has the opposite effect and reduces the release of pro-inflammatory factors that favors SH-SYSY cell survival (146). Similarly, BV2 cells are less activated after exposure to A\( \beta \) peptide or LPS stimulation when \( \gamma \)-GCL is up-regulated, leading to augmentation of GSH (127, 329). Correspondingly, the expression of pro-inflammatory signals such as TNF, IL-1\( \beta \) and iNOS is reduced in \( N \)-acetyl cysteine-treated rats during experimental stroke compared with that in vehicle-treated animals (125). Taken together, these studies illustrate the direct link between oxidative signaling and the activation profile of microglial cells.

The GSH pool plays a critical role in chronic inflammation linked to neurodegenerative diseases and, thus, represents a potential target for treatment. This view arises from the results of numerous studies in which the depletion of brain GSH has been recorded using N9 microglia, although it was noted that mitochondrial GSH was unaffected by the drop in total GSH after LPS/IFN-\( \gamma \) treatment (266). Recent evidence shows that several flavonoid extracts from Rhus verniciflua were effective in preventing glutamate-mediated toxicity and oxidative stress in microglial cells in vitro (46).

C. Microglial phenotypes and the glutathione pool

Several studies report that microglial activation alters the GSH pool, although the response differs among cell lines. For instance, LPS/IFN-\( \gamma \)-induced activation of iNOS in both enriched primary microglial cultures and the N11 microglial cell line elicits a 40% decrease in GSH that can be blocked by the inhibition of iNOS (44, 200, 214). Similar observations have been recorded using N9 microglia, although it was noted that mitochondrial GSH was unaffected by the drop in total GSH after LPS/IFN-\( \gamma \) treatment (266). However, in BV2 microglial cells, the depletion in GSH in response to LPS/IFN-\( \gamma \) was independent of NO production (200). Furthermore, two independent studies have shown that TNF treatment of primary microglial cells in culture produced a significant increase in GSH that was accompanied by a significant reduction in ROS levels (75, 235). The opposite occurred in oligodendrocytes, and it was concluded that signals from TNF induce an antioxidant response in microglia which is absent in oligodendrocytes.

There are several instances in which changes in the GSH pool alter the extent of microglial activation. Thus, depletion of GSH in human microglial cells with the \( \gamma \)-GCL inhibitor buthionine-S-sulfoximine (BSO) induces oxidative stress and an inflammatory response that causes the cells to secrete TNF, IL-6, and nitrite ions which are toxic to neuroblastoma SH-SYSY cells (145). A similar response occurs in astrocytes, which in both cell types is linked to calcium influx through TRPM2 channels. As expected, the stimulation of GSH synthesis in microglia has the opposite effect and reduces the release of pro-inflammatory factors that favors SH-SYSY cell survival (146). Similarly, BV2 cells are less activated after exposure to A\( \beta \) peptide or LPS stimulation when \( \gamma \)-GCL is up-regulated, leading to augmentation of GSH (127, 329). Correspondingly, the expression of pro-inflammatory signals such as TNF, IL-1\( \beta \) and iNOS is reduced in \( N \)-acetyl cysteine-treated rats during experimental stroke compared with that in vehicle-treated animals (125). Taken together, these studies illustrate the direct link between oxidative signaling and the activation profile of microglial cells.

The GSH pool plays a critical role in chronic inflammation linked to neurodegenerative diseases and, thus, represents a potential target for treatment. This view arises from the results of numerous studies in which the depletion of brain GSH has been recorded using N9 microglia, although it was noted that mitochondrial GSH was unaffected by the drop in total GSH after LPS/IFN-\( \gamma \) treatment (266). Recent evidence shows that several flavonoid extracts from Rhus verniciflua were effective in preventing glutamate-mediated toxicity and oxidative stress in microglial cells in vitro (46).
elevation in GSH compared with astrocytes that suggests a heightened sensitivity to the toxin in these cells.

V. Oxidized Lipid By-Products and Chronic Inflammation

Neural membranes are believed to be a Pandora’s box with a wide spectrum of lipid mediators whose activities range from neuroprotective to neurotoxic effects (20). These mediators include free fatty acids such as arachidonic acid (AA), DHA, and lyso-glycerophospholipids (prostaglandins, leukotrienes, and platelet activating factor). While AA and lyso-glycerophospholipid metabolites are mostly pro-inflammatory, DHA metabolites (resolvins, lipoxins, and neuroprotectins) have primarily anti-inflammatory properties (85). The protective ability of resolvins and neuroprotectins lies in their capacity to inhibit IL-1β-induced NF-κB and COX-2 expression (176). In addition, DHA and eicosapentaenoic acid have been shown to reduce chronic inflammation, probably by decreasing IkB phosphorylation, thus attenuating NF-κB (65, 85).

A. Microglia can induce lipid peroxidation

As indicated in other sections of this review, NOX and iNOS activation in microglia lead to the generation of ROS and RNS, which combine together and form ONOO-. In fact, ONOO- production may be quantitatively more relevant than O2− and H2O2 production, at least in rodents (32). As shown in Figure 7, ONOO- further decomposes to highly reactive radicals—nitrogen dioxide radical (●NO2), ●OH, and carbonate radical (●CO3). Each of these radicals has the potency to induce lipid peroxidation (96), a multistep autocatalytic process that results in the generation of oxysterols, hydroperoxides, and endoperoxides. The latter is further metabolized into a variety of reactive α,β aldehydes (4-hydroxy-2-nonenal [HNE], and acrolein [ACR]), dialdehyde such as malondialdehyde (MDA) and glyoxal, and keto-aldehydes (4-oxo-trans-2-nonenal, and isoketals) (93). Unlike ROS, reactive aldehydes are relatively stable and can diffuse from the original site of injury, thus spreading the initial oxidative damage (224). Notwithstanding the past two decades of extensive research in the field of reactive aldehydes, their role and function in cell biology remains largely unexplored. Of the three major aldehydes, HNE is the best characterized and participates in many signaling pathways that regulate cell physiology (236). Despite the fact that ACR is 100 times more reactive than HNE, its association with several brain pathologies, including neurodegenerative disease, is only beginning to be understood (60). MDA is, on the other hand, almost completely neglected from the viewpoint of its role as a signaling molecule.

To date, there has been little work done on analyzing the specific effects of lipids and their derivatives on microglial function. Nevertheless, several in vitro studies have highlighted their importance in the onset of neurodegeneration (Fig. 7). Thus, using an in vitro model of PD, Kim and colleagues (128) revealed that microglia are attracted by lipid components released from dying dopaminergic neurons. Similarly, lysophosphatidic acid was found to act as chemoattractant for microglial cells (276). The significance of lipid peroxidation products in neurodegeneration is further reinforced by the fact that both HNE and ACR are able to induce glutamate release from activated cultured microglia (15). Namely, as has been already discussed, an increase in extracellular glutamate arising from M1 microglia leads to neural degeneration mediated by HNE. On the other hand, DHA has displayed modulatory effects on the inflammatory properties of activated microglia through reduced secretion of pro-inflammatory cytokines and NO and an increase in the GSH pool (239). The only neurodegenerative disorder where lipid peroxidation products (HNE, 4-hydroxyhexenal and crotonaldehyde) were found present in microglia is ALS (287, 352). It seems that in the context of lipid peroxidation, microglia is explored predominantly as a source of highly reactive radicals which are able to initiate this process. Major oxidized lipid by-products related to chronic neuroinflammation are discussed next.

1. 4-Hydroxy-2-nonenal. As a product of ω-6 polyunsaturated fatty acid peroxidation, HNE is a second messenger of free radicals due to its involvement in cell signaling under normal and pathological conditions (82, 208, 354, 357, 358). The participation of HNE in brain pathologies is at the moment mostly explored in the context of AD, ranging from mild cognitive impairment (MCI), through early stage AD (EAD) and late AD (LAD). Reed et al. were the first to identify specific HNE-bound proteins in hippocampus and inferior parietal lobe from MCI patients, some of which were significantly elevated compared with the control (259). Throughout the course of AD, several significant categories of proteins were found to be HNE modified. While in MCI these categories include energy metabolism, mitochondrial dysfunction, cytoskeletal integrity, antioxidant defense, protein synthesis, stress response, neuronal communication, and excitotoxicity, EAD is mainly characterized by HNE-modified proteins that are involved in energy and mitochondrial dysfunction. In the LAD, proteins involved in antioxidant defense and cytoskeletal integrity appear to be HNE modified (33). Increased levels of free HNE were observed in the amygdala, hippocampus, and parahippocampal gyrus of AD brain compared with age-matched controls. This increased alkenal concentration corresponded to the regions showing the most striking histopathologic alterations in AD (181). With regard to other neurodegenerative diseases, HNE was detected immunohistochemically in 58% of surviving neurons of substantia nigra from individuals affected by PD, as compared with 9% in control subjects (355). Besides this, HNE adducts were found in Lewy bodies in neocortical and brain stem neurons of PD patients (41). Moreover, HNE alters dopamine uptake after binding to sulfhydryl groups of the dopamine transporter and, therefore, may affect the onset and progression of PD (354). In another disease with a very strong inflammatory component, MS, a post-mortem analysis likewise revealed HNE in early and actively demyelinating plaques (210). Even though free HNE was not detected in MS, a large accumulation of both lysine and histidine HNE adducts was observed, implying a role of HNE in protein modifications (336). Finally, increased levels of HNE adducts were also found in Huntington disease (HD) (260). Together, these observations suggest a very significant production of HNE under inflammatory conditions as well as its participation in several proteinopathies, including AD, PD, and HD.

2. Acrolein. Unlike HNE, ACR has many sources of origin. It is not only formed during incomplete combustion of
petrol, coal, wood, and plastic material but is also present in cigarette smoke and formed in overheated frying oils. ACR is a known metabolite of the widely used anticancer drug cyclophosphamide and can be formed intracellularly by enzymatic oxidation of polyamine metabolites. As a result, only a small part of ACR in the cell results directly from lipid peroxidation (82). Nevertheless, its role in numerous pathologies is becoming more pronounced. With regard to neurodegenerative diseases, ACR has been mostly studied in AD. Thus, more than half of neurofibrillary tangles in AD cases showed strong ACR immunoreactivity (39). A significant increase in extractable ACR in AD amygdala, hippocampus, and para-hippocampal gyrus was observed compared with age-matched controls (162). ACR increases in a disease progression-dependent manner in AD. Significantly elevated ACR levels were found in superior and middle temporal gyrus during MCI with expansion to hippocampus and parahippocampal gyrus in EAD (337). Besides protein adducts, ACR can induce DNA modifications, resulting in ACR-deoxyguanosine adducts. An increase in these adducts was demonstrated in brain tissue from AD patients, implying their role in mutagenesis and carcinogenesis and thus contributing to the pathogenesis of neurodegenerative diseases (159). With regard to neurodegenerative diseases, ACR has been mostly studied in AD. Thus, more than half of neurofibrillary tangles in AD cases showed strong ACR immunoreactivity (39). A significant increase in extractable ACR in AD amygdala, hippocampus, and para-hippocampal gyrus was observed compared with age-matched controls (162). ACR increases in a disease progression-dependent manner in AD. Significantly elevated ACR levels were found in superior and middle temporal gyrus during MCI with expansion to hippocampus and parahippocampal gyrus in EAD (337). Besides protein adducts, ACR can induce DNA modifications, resulting in ACR-deoxyguanosine adducts. An increase in these adducts was demonstrated in brain tissue from AD patients, implying their role in mutagenesis and carcinogenesis and thus contributing to the pathogenesis of neurodegenerative diseases (159). With regard to PD, it has been reported that in the substantia nigra from PD patients, ACR-modified α-synuclein accumulates mainly in the cytoplasm of the nigral melanized neurons (283).

3. Malondialdehyde. The main source of MDA in biological samples is the peroxidation of polyunsaturated fatty acids with two or more methylene-interrupted double bonds. However, MDA can be also generated in vivo by enzymatic conversion from various prostaglandins (69). Several postmortem studies have shown elevated MDA levels in the hippocampus, pyriform cortex and amygdala, and temporal, frontal, parietal, and occipital cortices of the AD brain, as compared with young and age-matched controls (74). Serum levels of MDA have been suggested as markers of neurodegenerative processes. Indeed, increased MDA levels in serum of MCI, EAD, and LAD patients were observed (10, 220) and even erythrocyte MDA levels have been proposed as markers of cognitive deterioration (70). MDA immunoreactivity was seen in lipofuscin granules in neurons and macrophages in MS with additional staining predominantly present in myelin sheaths in active lesions (95). Increased MDA levels were also reported in the cerebrospinal fluid (CSF) of patients with PD (74).

4. Isoprostanes and neuroprostanes. Isoprostanes (IsoPs) are stable products of free radical reactions with AA, while neuroprostanes (NeuroPs) are oxidation products of DHA. NeuroPs provide a unique window for quantification of oxidative damage primarily in neuronal membranes in vivo (180). Total NeuroP, but not total IsoP, levels were found to be greater in AD patients than in controls, but only in those brain regions involved by AD (198). On the contrary, in MCI, increased IsoPs levels were detected in middle frontal gyrus, inferior parietal lobule, and occipital area compared with controls. In addition NeuroPs were elevated in the same areas, besides middle frontal gyrus, including hippocampus (180).

Taking into consideration the earlier mentioned implications of oxidized lipids in neurodegenerative disorders characterized by chronic inflammation, one can easily conclude that oxidized lipids have a far-reaching impact in the onset of these diseases. Affecting numerous proteins, most of which are still not identified, oxidized lipids interfere with the main signaling pathways that are responsible for the cell functioning. By elucidating the consequences that oxidized lipids and their metabolites have on the cell, we will be one step closer not only to determining the onset of the disease, but also to determining new therapeutic approaches.

VI. Redox Signaling Through Protein Sulphydryl Groups

Traditionally, ROS/RNS have been viewed as molecules that compromise normal cellular physiology as a result of damage to DNA, proteins, and lipids. However, it is becoming increasingly clear that protein modification by ROS/RNS does not occur indiscriminately and that certain cysteine residues in proteins are more prone to oxidative modification than others. Indeed, it has been suggested that low levels of ROS/RNS may act as signaling molecules by causing reversible and covalent modification of redox-sensitive proteins via cysteine residue(s) which are exposed on the surface of the protein. Figure 8 depicts the main changes of proteins through reversible and irreversible modification of their cysteine residues.

A. Protein-S-thiol modification

S-thiolation is an important means of protecting protein–SH groups from damage by oxidation, which, if not controlled, generates sulfenic (P–SOH), sulfenic (P–SO2H), or sulfonic (P–SO3H) acids. The extent of oxidation will depend on the cell oxidative level: high levels of ROS generate -sulfine and -sulfone derivatives, which are irreversible and
associated with oxidative damage. Low levels of ROS/RNS generate reversible protein-cys-sulfene derivatives. However, these are intrinsically unstable and are prone to further oxidation to sulfonic or sulfonic acids. They may also bind to vicinal thiols, forming intramolecular disulfide bonds or be scavenged by GSH, yielding P–S–S–G. This process is known as S-glutathionylation (syn. S-glutathiolation) and depends on the local supply of GSH ([59] and references therein). The mechanism of S-glutathionylation is not entirely clear, but at the concentration of GSH that pertains in most cells and particularly in microglia, spontaneous disulfide exchange is likely (318). In addition, there is evidence that enzymatically catalyzed S-glutathionylation may occur in conditions of severe oxidative stress. De-glutathionylation is commonly catalyzed by GR.

B. Protein-thiol modification as a signaling mechanism in microglia

To date, there are a few reports of protein thiol modification specifically in microglial cells, yet evidence is accumulating, primarily from studies on macrophages/monocytes that this is undoubtedly an important aspect of the cellular response to, and protection from, oxidative stress. However, there is a fine balance between physiological and pathological function and, in conditions where the GSH pool is depleted, for example in neurodegenerative diseases, partially oxidized proteins may react with oxygen or other oxidants and produce irreversibly oxidized sulfines and sulfones, thus exacerbating oxidative damage.

In 1994, Ravichandran et al. (257) demonstrated that glyceraldehyde-3-phosphate was transiently S-thiolated (most commonly by glutathione, but also by cysteine) minutes after the respiratory burst in monocytes. Since then, there have been several other reports on the impact of S-thiolation or nitrosylation on cellular function that include, in the main, the following areas: (i) microglial activation and recruitment; (ii) cytoskeletal rearrangements and cellular trafficking; (iii) regulation of signaling pathways; and (iv) regulation of transcription. For example, oxidative S-glutathionylation is critical in the tyrosine kinase-dependent signaling pathway, leading to β2-integrin CD11b (Mac-1) activation required for cell migration (29) and for modification of β-actin assembly (59). In addition, the E1 and E2 components of the ubiquitin-proteasome system are reversibly inhibited by S-glutathionylation during oxidative stress (217), causing dysfunction of the protein elimination pathway. Furthermore, the Rpn1 and Rpn2 subunits of the 19S regulatory particle of the 26S proteasomal pathway are inhibited by S-glutathionylation after exposure to H2O2 and GSH in neutrophils in vitro (377). With regard to signaling pathways, NO, produced in response to IFN-γ, activates JNK and p38 signaling cascades and is a prime example of cross-talk between regulation of protein phosphorylation and oxidative stress. Similarly, inactivation of calcium-calmodulin-dependent kinase 1 is achieved by S-glutathionylation of the active site cysteine (Cys179) (120). In macrophages, this kinase mediates the in vitro response to LPS and may also operate in vivo to regulate inflammation and organ dysfunction arising from sepsis (366). Similarly, most members of the PKC family of proteins contain several cysteine-rich regions in their catalytic and regulatory domains and, as such, are likely targets of modification by thiolation. Indeed, S-glutathionylation in vitro inhibits PKC isozymes, raising the possibility that GSH may be anti-tumourigenic via this mechanism (50). There are several examples of regulation of transcription by protein thiolation or nitrosylation. For example, redox-triggered reversible S-thiolation of transcription factor c-JUN regulates DNA binding (130). S-nitrosylation of karyopherin chromosomal region maintenance 1 (the major receptor for classical nuclear protein export) inhibits its interaction with nuclear export signals and blocks protein export from the nucleus (333). The human p53 tumor suppressor is inhibited by S-glutathionylation both in vitro and in human cancer cells as a result of oxidative stress (323). Other regulators of the inflammatory response, for example the transcription factor NFKB, are also influenced by S-thiol modification and are discussed in greater detail in Section VII.

An example of protein-thiolation in a pathological context comes from the observation that an oxidative burst in BV2 murine microglial cells leads to S-glutathionylation-mediated inhibition of insulin degrading enzyme and reduced degradation of Aβ peptide, with direct implications for progression of AD (254). Similarly, nitrosylation can also be associated with disease. For example, α-synuclein, the chief component of Lewy bodies released from damaged dopaminergic neurons in PD, is nitrosylated as a result of oxidative stress, and this initiates an inflammatory response in microglia (261).

In summary, S-glutathionylation and nitrosylation represent significant mechanisms for controlling the activity of microglia in a wide range of contexts and play an important role in determining cell fate and responsiveness to oxidative stress.

C. Thioredoxin reductase system

The thioredoxin reductase (TrxR) system comprises thioredoxin (Trx), TrxR, and NADPH, which, in mammalian cells, is derived from the pentose phosphate pathway and, to a lesser extent, by the malic enzyme. Trxs are a small family of redox-active proteins (10–12 kDa) that are critical for maintaining cellular redox balance and antioxidant function, including control of oxidative stress and cell death. While few, if any, studies have been performed with microglial cells, it is highly likely that this system plays an important role in the respiratory burst and protection of the cell from oxidative stress.

The redox activity of Trx is due to the presence of a highly conserved catalytic site with the sequence Trp-Cys-Gly-Pro-Cys-Lys. The negative redox potential of the two cysteine residues provides a strong reducing environment whose purpose is to protect protein-SH from oxidation and/or recycle S-thiolated proteins. Two forms of Trx exist in mammalian cells: Trx-1, which localizes to the cytoplasm, and Trx-2, which is found in mitochondria. In addition to recycling S-thiolated proteins, Trx has a number of additional roles, including acting as a co-factor in DNA synthesis by
Hággblad et al. adopted a genomics-based approach in an effort to identify targets of Trx. Trx-reduced disulfides were discovered among a number of well-known proteins, including peroxiredoxin (Prx) and cyclophilin (94). In addition, a number of ribosomal proteins were identified, suggesting that Trx plays an active role in the regulation of translation. Dehydroascorbate reductase, the enzyme that re-generates vitamin C from dehydroascorbate, was also identified as an important target, implying that the Trx system is involved in the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorbate-glutathione cycle. Additional Trx targets include oxidized protein tyrosine phosphatases, for example, PTP1B. In certain cell signaling cascades, the production of oxidized protein tyrosine phosphatases, for example, the ascorb
FIG. 10. Redox regulation of NF-κB. ROS may activate or inactivate the IKK complex through phosphorylation or cysteine oxidation, respectively, leading to modulation of downstream targets. On the other hand, ROS influence the DNA-binding properties of the NF-κB proteins. (i) phosphorylation of p65 on two serine residues mediated by ROS leads to greater NF-κB activation; (ii) oxidation of p50 prevents its DNA binding, and this oxidation is reversed in the nucleus by a Trx1-dependent process. Trx, thioredoxin.

In vitro cultures of macrophages and to a lesser extent of microglia and will be presented here on the assumption that NF-κB regulation is similar in these two monocytic cell types (Figs. 10 and 11). In addition, some of these general mechanisms may take place in neurons.

ROS activates upstream kinases that lead to NF-κB activation. Among those are IKKβ and probably IKKe, which create phosphorylate-specific serines in the NF-κB inhibitor IκBz. This phosphorylation targets IκB for degradation through the ubiquitin/proteasome pathway, thus relieving NF-κB from this constrain, and enabling NF-κB stabilization and nuclear translocation (362). Other kinases that participate indirectly in phosphorylation of NF-κB isoforms or regulate NF-κB indirectly through the IKK pathway include the Mitogen-activated protein kinase/ERK kinase-1 (209), AKT (121), PKC (73, 137, 149), CK2 (122), and PKA (370). The phosphorylation of the p65 isoform of NF-κB on Ser276 is necessary for the interaction of p65 with co-activators such as CBP/p300s required for the expression of a subset of NF-κB-dependent genes (216). PKA mediates phosphorylation of Ser276 (369, 371), and this event is considered dependent on ROS, as antioxidants inhibit Ser276 phosphorylation and CBP/p300 binding (114).

2. Redox state also controls NF-κB nuclear levels. ROS can influence the DNA-binding activity of NF-κB in the nucleus. Post-translational modifications of NF-κB are required for complex activation of NF-κB-dependent genes (91). Chromatin relaxation and remodeling are necessary for NF-κB binding to DNA, and transcriptional control is tightly regulated by acetylation/deacetylation of lysine residues in histone N-terminal tails. This regulation has been widely analyzed in lung macrophages. In resting monocyte cells, histone deacetylases (HDAC1)/p50 complexes bind to the DNA and repress transcription by local histone H3 deacetylation, which prevents RNA Pol II recruitment. On stimulation, p65 enters the nucleus, and associates with CBP/p300, leading to the displacement of p50/HDAC1 repressive complexes and enabling transcription (369). ROS levels profoundly alter HDAC1-3 function in activated macrophages, enabling NF-κB induction of pro-inflammatory genes (189, 347). The reduced HDAC2 activity is due to ROS-induced post-translational modifications such as nitration and nitrosylation (189, 347).

In addition to control of NF-κB levels, IKKz also regulates NF-κB nuclear stage in response to ROS. Macrophages stimulated with ROS inducers exhibited association of IKKz to the promoter of pro-inflammatory genes, leading to phosphorylation of Ser10 and acetylation of Lys9 on histone H3, enabling NF-κB interaction with DNA (348). Direct phosphorylation of p65 by PKA up-regulates the expression of a subset of NF-κB-dependent genes, including TNF, macrophage inflammatory protein 2, and monocyte chemotactic protein-1 (216). Phosphorylation of p65 in Ser276 by PKA enables an interaction of nuclear p65 with the co-activator CBP/p300 and, therefore, stimulates pro-inflammatory gene transactivation (369). This step is also regulated by the redox state, because antioxidant compounds impair PKA-induced phosphorylation of p65 at Ser276 and subsequent gene activation (114). Another post-translational modification that can occur is tyrosine nitration of p65 at two different tyrosines (Tyr66 and Tyr152) located in the RHD domain. Nitration of p65 results in the replacement of p65/p50 with the p50/p50 complexes or the association of p65 with IκBz that export NF-κB back to the cytosol (91). Cys32 of p50 provides another brilliant example of how cells use redox and S-thiol protein modification to control gene expression. Cys32 within the RHD domain of p50 should be reduced for efficient NF-κB DNA binding (311). In the cytoplasm of resting cells, Cys32-32 p50 is highly oxidized, but once NF-κB enters the nucleus,
Cys\textsuperscript{62} is reduced by Trx (242) or AP endonuclease/redox factor 1 (6, 103). Interestingly, the same example illustrates how S-thiol modification by NO is used as a negative feedback mechanism to switch off pro-inflammatory signaling induced by NF-κB. NO production on cytokine stimulation is associated with S-nytrosylation of Cys\textsuperscript{62}-p50 and Cys\textsuperscript{38}-p65 (123) that could be prevented with antioxidant compounds.

A corollary of the previous data is that redox state governs microglial activation toward a pro-inflammatory or alternative phenotype. In the presence of ROS signaling molecules, more p65/p50 dimers should be formed, leading to pro-inflammatory gene transcription. On the contrary, under homeostatic redox conditions, p65 will not be available and other NF-κB dimers such as p50/p50 will be formed, leading to increased expression of anti-inflammatory genes.

**B. NRF2 transcription factor**

Redox homeostasis is tightly controlled by the transcription factor NRF2, which is a crucial player in the antioxidant protection of microglial cells, thus avoiding pernicious effects of oxidative stress and over-activation of the M1 phenotype.

NRF2, a member of the Cap’n’Collar family of basic region-leucine zipper transcription factors, was cloned by virtue of its binding to the promoter of the \( \beta \)-globin coding gene (\( HBB \)) that was necessary for erythropoiesis and platelet development (197). However, its function is not related to erythropoiesis, but to control of redox homeostasis and it is currently viewed as the master regulator of the antioxidant response. NRF2 binds to a cis-acting element termed the ARE and modulates transcription of its target genes (268). In addition, NRF2 requires a member of the small MAF proteins (F, G or K in vertebrates) in order to form a functional ARE-binding transcriptional complex (345). Over the past decade, information on NRF2 antioxidant function has been obtained from studies with NRF2-deficient mice. NRF2 deficiency substantially increases susceptibility to a broad range of chemical toxins and disease conditions associated with oxidative pathology, whereas pharmacological activation of NRF2 protects against oxidative damage (305).

Although NRF2 is ubiquitously expressed, it has a very significant role in the context of microglial redox homeostasis. ARE-regulated genes include (i) enzymes involved in ROS clearance such as SOD3, GPx, and Prx; (ii) enzymes that synthetize reducing factors, such as GSH (catalytic and regulatory subunits \( \gamma \)-GCL), NADPH (glucose-6-phosphate dehydrogenase, and phosphogluconate dehydrogenase); (iii) enzymes related with the regeneration of reduced cofactors and proteins, for example, reduction of GSSG by GR; (iv) reduction of oxidized Trx by TrxR and Prx-S\textsubscript{O\textsubscript{2}-H} by sulfiredoxin; (v) redox transporters, such as X\textsubscript{c\textsuperscript{\textsuperscript{-}}}; (vi) metallothioneins (MT1 and 2) and ferritin, responsible for clearing metals by chelation reactions; and (vii) enzymes directly related with production of antioxidant molecules such as HO-1, NAD(P)H:quinone oxidoreductase 1 (NQO1), and Trx as well as inhibition of expression of Trx inhibitor (TXNIP). In addition, NRF2 also participates in the regulation of proteasomal protein degradation, cell proliferation, autophagy, and metabolic reprogramming (136, 166, 195, 301). The functions of NRF2 are summarized in Figure 12, and Figure 13 highlights the mechanisms that are known to regulate NRF2 activity at the levels of protein stability, phosphorylation, and epigenetic modifications.

### FIG. 12. NRF2 is the master regulator of the redox homeostasis

NRF2 modulates redox homeostasis through the control of a wide battery of cytoprotective genes that share in common ARE sequences in their promoter. SOD3, GPx, Prx, glutamate-cysteine ligase catalytic and modulator subunits (GCLC and GCLM), G6PDH, 6PGD, GSR, TrxR, Srx, cysteine/glutamate transport, metallothioneins (MT1 and 2), FT, HO-1, NQO1, \( \gamma \)-GT, \( \gamma \)-GS, Trx, and Trx inhibitor (TXNIP), 6PGD, phosphogluconate dehydrogenase; FT, ferritin; G6PDH, glucose-6-phosphate dehydrogenase; GCLC, glutamate-cysteine ligase catalytic subunit; GCLM, glutamate-cysteine ligase modulatory subunit; GSR, glutathione reductase; HO-1, heme oxygenase-1; Prx, peroxiredoxin; Srx, sulfiredoxin; TrxR, thioredoxin reductase; \( \gamma \)-GS, \( \gamma \)-glutamylcysteine synthetase.

1. **ROS control the NRF2 through redox modification of Kelch-like ECH-associated protein 1.** In surveillance mode, microglia maintain low NRF2 protein levels by a well-established mechanism that requires the participation of the ubiquitin E3 ligase adapter Kelch-like ECH-associated protein 1 (KEAP1). KEAP1 associates with the N-terminal region of Cullin3 (CUL3), a subunit of the ubiquitin E3 ligase complex, and promotes the ubiquitination of NRF2 in cooperation with the CUL3-ROC1 complex, resulting in proteasomal degradation (57, 87, 131, 361).

The interaction between NRF2 and KEAP1 occurs via a “two-site tethering” mechanism, otherwise known as the “hinge and latch” mechanism. In this model, two NRF2-motifs, ETGE and DLG, interact with a separate Kelch-repeat domain present in the KEAP1 homodimer. It is thought that a single NRF2 polypeptide first binds one KEAP1 subunit through its high-affinity ETGE motif, and that this, in turn, enables the second low-affinity DLG motif to engage with the other Kelch-repeat domain of the remaining KEAP1 subunit (186, 313). The interaction between
KEAP1 and NRF2 is controlled by the redox status of at least three critical cysteine residues of KEAP1 (Cys\textsuperscript{151}, Cys\textsuperscript{273}, and Cys\textsuperscript{288}). When these cysteines are oxidized or participate in adduct formation with electrophilic compounds, the NRF2/KEAP1 interaction is disrupted in a way that NRF2 escapes degradation, enters the nucleus, dimerizes with small MAF proteins, and binds AREs in its target genes (132, 153, 346, 360). Microglial activation of NOX results in increased ROS levels that lead to modification of KEAP1 cysteines and further activation of NRF2.

Pharmacological regulation of the KEAP1-NRF2 complex has been crucial for understanding the physiological role of NRF2. For instance, sulforaphane (SFN) has been successfully used to increase NRF2 levels in the brain. SFN is an isothiocyanate derived from broccoli that crosses the BBB efficiently enough to induce NRF2 and its target genes in the brain parenchyma (111). Intraperitoneal administration of SFN in wild-type mice, but not in NRF2-null mice, protects against MPTP-induced death of nigral dopaminergic neurons. Interestingly, the neuroprotective effects are accompanied by a decrease in M1 markers of reactive microglia (116). A large number of other plant antioxidants and plant-derived dietary supplements have been reported to target the KEAP1/NRF2 complex and might have a therapeutic value in the modulation of microglial activation (150, 274).

2. NRF2 regulation by signaling kinases. NRF2 is controlled by signaling kinases that are closely regulated by ROS/RNS levels. For instance, PERK and PKA kinases, activated by misfolded proteins or phorbol esters, respectively, as well as PKC phosphorylate NRF2 and disrupt the association of NRF2 with KEAP1 (58, 107). Other kinases such as CK2 (7), Fyn (113), or MAPKs (124, 286, 299, 344, 375) phosphorylate NRF2 without altering its interaction with KEAP1.

In recent years, Cuadrado’s group has reported that glycogen synthase kinase-3 (GSK-3)\textsubscript{β}, a kinase abnormally active in AD, inhibits NRF2 by nuclear exclusion (270). Additional studies have shown that GSK-3\textsubscript{β} phosphorylates NRF2 and activates an alternative degradation pathway that is dependent on a different E3-ligase named β-TrCP.
repeat containing E3 ubiquitin protein ligase (51, 252, 253). The physiological relevance of the inhibition of NRF2 by GSK-3β is reflected in two studies where GSK-3β decreased NRF2 activity, thereby sensitizing neurons against oxidative damage (111, 263).

GSK-3β activity profoundly influences microglial physiology. Thus, inhibition of GSK-3β by genetic or pharmacological approaches reduces the induction of M1 markers in response to different challenges, including LPS, traumatic injury, or 6-OHDA, and this is accompanied by a reduction in brain inflammation. These inflammatory challenges fail to increase typical M1-markers when GSK-3 is inactive and, therefore, NRF2 is active (108, 134, 331).

3. Epigenetic modulation of NRF2. A growing body of evidence supports the existence of novel mechanisms to modulate NRF2 other than proteasomal degradation. In 2009, Zhang’s group demonstrated that NRF2 is directly acetylated by CBP/p300 within the DNA-binding domain that augments binding of NRF2 to the AREs (298). In addition, H_{2}O_{2} released by M1 microglia can up-regulate the protein p300/ CBP and down-regulate HDACs. These events lead to increased binding of NRF2 to AREs (190). Astrocyte-rich cultures treated with conditioned medium from M1 microglia showed a time-dependent increase in astroglial HDAC activity that correlated with reduced acetylation of histones H3 and H4 and a further decrease in NRF2-related transcription (55). Accordingly, HDAC inhibition increased the expression of NRF2-target genes, Hmox1 (encoding HO-1), Nqo1, and Gclm. In contrast to wild-type animals, NRF2-deficient mice are not protected by pharmacological inhibition of HDAC after cerebral ischemia (330).

Methylation of cytosine-guanine (CG) islands within the NRF2 promoter has been shown to suppress its expression in mice with prostate cancer. Interestingly, NRF2 activity is restored by phytochemicals that reduce methylation of CG islands (297). With regard to oxidative stress, AD patients display high homocysteine and low vitamin B_{12} and folate levels in blood, suggesting a dysregulation of the S-adenosyl methionine cycle that is required for DNA methylation (275). Considering that the NRF2/HO-1 axis is up-regulated in AD microglia, the correlation between high NRF2 levels and lower methylation of NRF2 promoter sequences is reasonable.

NRF2 regulation by specific miRNAs is just beginning to be explored. Of note, miR153, miR27a, miR142-5p, and miR144 reduce NRF2 activation (206). Interestingly, miRNA metabolism is sensitive to oxidative stress and, therefore, may play a role in controlling NRF2 levels in microglia. It has recently been shown that Dicer, a key enzyme for the synthesis of mature functional miRNA, is down-regulated by aging and as a result of oxidative stress elicited by H_{2}O_{2}. Interestingly, in the same study, the authors show that the recovery of redox balance restored Dicer expression (319).

It is noteworthy that all mechanisms which are known to regulate NRF2 are sensitive to redox status. It is speculated that the increase in ROS/RNS levels during execution of the M1 program increases pro-inflammatory gene expression through the NF-κB pathway, as well as anti-oxidant gene expression by NRF2. This dual mechanism enables microglia to be primed to shut down the immune response and to return to a resting or surveillance state.

4. NRF2 and its target genes modulate microglial phenotypes. The first evidence for an immunomodulatory role for NRF2 was reported in models of lung inflammation. Genetic deficiency in NRF2 enhanced susceptibility to emphysema (45, 112, 255), diesel exhaust chemicals (152), and asthma (256). Accordingly, NRF2-null mice are more susceptible to the inflammatory response elicited by LPS and sepsis (307, 308). Considering this background and that microglia belong to the monocyte lineage, it follows that NRF2 should also participate in the final acquisition of microglial phenotype. This was demonstrated by comparing parameters of inflammation in the hippocampus of NRF2-deficient and wild-type mice after systemic treatment with LPS. NRF2-knockout mice were hypersensitive to neuroinflammation induced by LPS, as determined by an increase in M1 typical markers, including F4/80, iNOS, IL-6, and TNF, compared with wild-type littermates. In line with these observations, NRF2 activation by SFN reduced the abundance of microglial cells in the hippocampus and attenuated the production of M1 markers in response to LPS (111).

With regard to neurodegenerative disorders, it has been reported that, as with LPS, chronic administration of MPTP i.p. resulted in enhanced microglial release of proinflammatory cytokines. This observation correlated with enhanced generation of M1 mediators in primary microglial cultures of NRF2-null mice compared with wild-type littermates. Interestingly, SFN administration prevented chronic inflammation only in the wild-type animals, providing formal proof that oxidative stress and NRF2 are definitely associated with the etiopathology of several neurodegenerative diseases. At the same time that M1 inflammation markers were increased in response to MPTP, M2 markers were decreased in NRF2-null mice compared with wild-type animals. These results have been confirmed in microglial cultures that are stimulated with conditioned medium from dopaminergic cells treated with MPP^{+}, further demonstrating a role of NRF2 in maintaining a balance between classical and alternative microglial activation (262).

Among the NRF2 target genes, numerous data strongly implicate HO-1 in immunomodulation. HO-1 catalyzes the degradation of heme to generate carbon monoxide, biliverdin, and free iron (167). Biliverdin is transformed by biliverdin reductase into bilirubin, which is considered one of the most powerful antioxidant molecules (168, 169). Carbon monoxide released by glial cells after induction HO-1 underlies its role in controlling monocyte activation, because carbon monoxide and biliverdin inhibit NOX (138, 302) and TLR-4 (204) signaling. Furthermore, HO-1 might regulate NOX via the reduction of heme availability (303). In the brain, astrocytes secrete factors that increase microglial HO-1 protein levels and lead to a reduction of microglial ROS in response to IFN-γ (194). Moreover, heme oxygenase activation increases prostaglandin production in rat astrocytes through the activation of COX enzymes (171), which is one of the earliest events during neuroinflammation (243). On the other hand, cyclopentanone prostaglandins induced HO-1 in both astroglia and microglia, thus amplifying the inflammatory response (129, 133).
Polarization of monocytes by viral IL-10 results in up-regulation of HO-1 and acquisition of M2c. HO-1 inhibition results in a loss of capacity of IL-10 to suppress TNF and IL-1 production reducing alternative M2c activation (9). Both heme regulatory molecules, CD163 and HO-1, are preferentially expressed by M2-macrophages (288). This interesting observation is also supported in microglia, where CD163- and HO-1-positive cells preferentially activate the M2 program after traumatic brain injury (367). It is interesting that recent evidence indicated that HO-1 and biliverdin reductase undergo oxidative, nitrosative, and phosphorylative post-translational modifications in the brain of subjects with AD and MCI (17, 18). Although those studies did not identify the cell type where these post-translational modifications occur, they suggest that the anti-oxidant and anti-inflammatory roles of these two enzymes may be lost, at least partially, in the AD brain.

Emerging evidence indicate a strong relationship between redox homeostasis and the vitagene system. Vitagenes constitute a network genes participating in longevity assurance processes (36). The vitagene family includes several NRF2 regulated genes such as Hmox1 and Trx, as heat shock protein Hsp70 and sirtuin (Sirtl). Its participation in modulation of neuroinflammation is being now characterized. For instance, Hsp70 induces IL-6 and TNF production, phagocytosis, and clearance of Aβ peptides by microglia. Activation of SIRT1 decreases Aβ-induced neuronal death and transgenic over-expression of SIRT1 in AD models increases processing of APP through the non-amyloidogenic route (54). On the contrary, SIRT2 overexpression inhibited microglial activation and brain inflammation in response to LPS through NF-κB deacetylation (222). The vitagene system can be activated by nutritional antioxidants, including curcumin, resveratrol, acetyl-L-carnitine, or carnosine (35, 37).

On the other hand, NF-κB, the master regulator of inflammation, is hyperactivated under oxidative stress conditions and, therefore, is sensitive to modulation by NRF2. We and others have reported the hyperactivation of p65-NF-κB in NRF2-deficient microglia/macrophages as well as the down-regulation of p65-NF-κB by NRF2 inducers such as SFN. This functional interference has not yet been convincingly characterized at the molecular level. Thus, while NF-κB is the master regulator of the M1 phenotype, NRF2 may be a master regulator of the M2 phenotype.

**VIII. BBB Permeability Is Altered by ROS, Enabling Homing of Peripheral Immune Cells**

For many years, the brain was one of the several organs described as immunologically privileged on the basis that allo- and xeno-grafts transplanted into the CNS are “in some way partially or fully exempted from the normal rigors imposed by their histoincompatible status” (16). In the early years of the twentieth century, Murphy and Sturm (202) proposed two possible explanations: (i) mechanical impediment of cells to migrate beyond the perivascular spaces; (ii) lymphoid cells find the brain tissue an uncongenial environment. These authors were the first to define BBB as an “anatomic barrier that restricts diapedesis” and ensures the immune privileged state of the brain. The lack of constitutive MHC class I and II expression on CNS parenchymal cells (molecules required by T cells to recognize their antigen), the inability of microglial and astroglial cells to sustain immune responses, the paucity of dendritic cells in the parenchyma, and the lack of lymphatic vessels within the CNS further contributed to the concept of an immune privileged tissue, inaccessible to circulating immune cells (79, 201). However, this view was questioned as early as 1948 by Medawar (188), who concluded that T cells activated outside the CNS found a way across the brain barriers to provoke an immune response within the CNS (81). These days, it is known that leukocytes, monocytes, and macrophages can enter the CNS, not only during inflammation and disease (79, 279), but also under homeostatic conditions. In such non-disease states, leukocytes accumulate on the abluminal side of CNS microvessels (219), where they encounter perivascular antigen-presenting cells, collect CNS antigens, and patrol the CNS barriers (92). Infiltrated cells then act together with resident microglia (63) and even in some cases, adopt a microglial phenotype (88, 101).

There are several routes for leukocytes to enter the CNS: (i) migration from the microvessels into parenchymal perivascular space; (ii) migration via the choroid plexus into the cerebro-spinal fluid; and (iii) migration through post-capillary venules at the pial surface into subarachnoid and Virchow–Robin perivascular spaces. A fourth route has been recently suggested that involves migration from subependymal vessels via the ependyma into the ventricles (304). These routes involve crossing the endothelial BBB, the epithelial blood–CSF barrier, and the blood–spinal cord barrier.

**A. Blood–brain barrier**

Localized at the interface between the blood and the cerebral tissue and formed by the endothelial cells (ECs) of cerebral blood vessels, the BBB is, by far, the largest surface area for blood–brain exchange (12–18 m² in the adult human) (203). Moreover, the maximal distance between brain cells and a capillary is about 25 μm, meaning that once the BBB is crossed, the distance for diffusion of solutes and drugs to neurons and glial cell bodies is short (1). The integrity of the BBB is controlled by functional interactions of several cell types residing in close proximity to brain ECs (pericytes, astrocytes, neurons, and microglia). All these cells, along with the basal lamina (endothelial basement membrane), constitute the neurovascular unit (335). Figure 14 shows the elements that constitute the BBB and its alteration by ROS.

The cerebral ECs differ significantly from ECs of other organs by having specialized transport systems, uniform thickness with no fenestrations, low pinocytic activity, continuous intercellular tight junctions (TJs) and adherens junctions, and greater number and volume of mitochondria (64). Astrocytes secrete and provide important factors to ECs, including TGF-β, glial-derived neurotropic factor, and fibroblast growth factor, which modulate the BBB to control the passage of most molecules (2, 304). On the other hand, the regulation of BBB formation in embryogenesis, its maintenance, vascular stability, regulation of capillary blood flow, angiogenesis, and clearance of toxic cellular products are under the control of pericytes (338).

**B. Oxidative stress affects BBB permeability**

Under non-pathological conditions, the BBB maintains the ionic composition of the brain interstitium that is necessary
for normal neuronal function. However, almost every CNS pathology (MS, hypoxia and ischemia, edema, stroke, PD, AD, epilepsy, tumors, glaucoma, and lysosomal storage diseases) includes an element of BBB dysfunction ranging from mild and transient TJ opening to chronic barrier breakdown or even changes in transport systems and enzymes (1, 72, 376).

One of the earliest steps preceding clinical diagnosis of neurodegenerative disorders seems to be disruption of BBB caused by oxidative stress (97, 161, 280). ROS have been shown to modulate BBB integrity by transient activation of PI3K/AKT pathway via RhoA, which acutely disrupts the integrity of the TJs, as indicated by the disappearance of occludin and claudin-5 (280). The inhibition of Rho kinase completely prevented the ROS-induced increase in permeability and the ROS-induced polymerization of the actin cytoskeleton (119). The increase in BBB permeability correlates with the down-regulation of occludin expression (135), alterations in the oligomeric assembly of the occludin (185), and its movement away from the TJs (161). In fact, occludin is degraded in response to $H_2O_2$-induced impairment of BBB function (156). Accordingly, IL-17-induced NOX- or xanthine oxidase-dependent ROS production activates the BBB-endothelial contractile machinery, which is accompanied by a down-regulation of occludin (109). The main enzymes responsible for TJ degradation are the matrix metalloproteinases (MMPs), which are also activated by ROS in a later phase of BBB disruption (97, 349). MMPs as well degrade collagen and laminin in basal lamina, causing the disruption of basement membrane and contributing to an increase in BBB permeability. In addition, increased ROS causes recruitment and migration of leukocytes to the CNS whose released products further degrade basal lamina and increase BBB permeability (76).

C. Activated microglia and BBB impairment

As discussed earlier, ROS produced from activated microglia can induce lipid peroxidation, thereby modulating the integrity of the BBB. For example, HNE was shown to affect functional integrity of the BBB, causing its permeability within 20 minutes in vitro (191). The mechanism was explained by Usatyuk et al. (320), who revealed that HNE modulates cell-cell adhesion through modifications of focal...
adhesion, adherens, and TJ proteins as well as integrins. These findings, along with HNE abundance in the BBB found under various pathophysiological circumstances (277, 356) and as shown in Figure 15, suggest that HNE is associated with several regulatory functions, including post-traumatic recovery (355, 359).

Studies on CD200 deficient mice have revealed that fine regulation of microglial activation occurs through an interaction of CD200 (mainly expressed on neurons) and its receptor CD200R (mainly expressed on microglia). Under inflammatory conditions, microglial activation in these mice is exacerbated, due to increases in TLR2 and TLR4 expression (56). This model has also shown that an increase in BBB permeability precedes microglial activation (71). Evidence suggests that microglial activation inevitably causes BBB impairment. Thus, Kacimi et al. (118) showed that activated microglia promote BBB disruption through injury of ECs by releasing high amounts of ROS. This mechanism was further explored in EAE, where fibrinogen leaking from the CNS was found to trigger microglial activation (61). This condition takes place before the onset of the neurological symptoms of EAE; whereas, at the peak of the disease, microglia start clustering around the vasculature in areas of fibrin deposition and release ROS, leading to axonal damage (61). These findings are in accordance with immunohistochemical and post-mortem magnetic resonance imaging analyses of human MS lesions where microglial activation and BBB disruption were identified as the earliest pathological signs (178, 325).

In the case of impaired BBB and microglial activation, there is a thin line between what happens first. Nonetheless, the microglial NOX system seems to be the major source of O$_2^-$ (28, 119). This species appears to be the most important ROS in cerebral diseases, causing not only BBB permeability but also enhancing monocyte adhesion and migration (322, 351).

D. Leukocyte trafficking across the BBB

The BBB might be considered well regulated but a delicate boundary between humoral and cellular components of “systemic integrative tissue of the organism” (blood) and the most sophisticated neuronal system that controls most of the major body functions and should, therefore, be well protected from potentially dangerous humoral and cellular components present in the blood. Even though leukocytes interact with ECs of the BBB within small capillaries, their extravasation into the brain parenchyma occurs at the level of post-capillary venules (79). Specifically, in pre- and post-capillary vessels, astrocytic endfeet of the glia limitans are separated from the endothelial layer by pericytes and smooth muscle cells and by the perivascular (Virchow–Robin) space (22). This perivascular space seems to serve as a specific “checkpoint” for immune competent cells before the delicate CNS milieu is put at risk for the benefit of successfully fighting a potential infection (79).

During various local and systemic stress conditions (hypovolemia, hypoxia, shock, sepsis, traumatic injury, etc.), humoral and cellular components of the blood collide with BBB and the neural tissue produces cytokines and soluble factors that act on microglia, astrocytes, or neurons, causing further immune system activation, in particular, affecting leukocytes [reviewed in (139)]. ROS, originating from microglia and leukocytes after their interaction with ECs, seem to be the key players in promoting leukocyte trafficking across the BBB through activation of redox signaling pathways. Namely, triggered inflammatory responses to altered BBB by both leukocytes and microglia lead to TNF production and expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and platelet/endothelial cell adhesion molecule 1 (PECAM 1) in ECs (139), TNF appears to be the major signaling mediator for endothelium activation and leukocyte recruitment as observed by a decreased number of rolling and adherent leukocytes (approximately 80%) after minocycline (effective inhibitor for microglial activation) treatment (372). In addition, sustained overexpression of pro-inflammatory cytokine IL-1β is also capable of inducing persistent leukocyte recruitment to the brain (282). As shown in the same study, BBB leakage is not reduced when neutrophil infiltration is abolished, indicating high importance of ROS and their second messengers (such as HNE), humoral factors (such as cytokines), and glial cells in BBB malfunction under stress (282). These data verify the fact that myriad of factors mainly induced by ROS affect not only BBB permeability but also immune cells crossing it.

Intravital fluorescence video microscopy has provided direct in vivo evidence of the unique interaction of T lymphocytes with the BBB in the spinal cord. Unlike the diapedesis across postcapillary venules in lymph nodes, diapedesis across the BBB lacks T-cell rolling and lasts approximately 6 h, rather than minutes (321, 339). Thus, instead of rolling, T cells were captured by the post-capillary venule wall, followed by firm adhesion to the venule. These events (capture and adhesion) are mediated through the interaction of α4-integrins on T cells with endothelial VCAM-1, whereas diapedesis of T cells across the venule wall is supported by the αLβ2-integrin (leukocyte function-associated antigen) (81, 140).
Constitutively expressed VCAM-1 mediates the G-protein-independent prompt arrest (capture) of circulating encephalitogenic T-cell blasts via α4-integrin to the endothelium of the healthy BBB (321). Transient capture is followed by G-protein-dependent α4-integrin/VCAM-1-mediated adhesion strengthening (321). Thus, leukocytes cross the brain endothelium, irrespective of the TJ presence, suggesting that BBB disruption and cell migration are not necessarily connected (339). After their diapedesed across the inflamed BBB, T cells need to make their way across the ECM components of the endothelial basement membrane. This membrane consists of a number of glycoproteins such as laminins, type IV collagen, nidogens, and heparan sulfate proteoglycans (80). Just recently, T-cell extravasation sites were shown to be preferentially the endothelium basement membrane sites containing laminin α4 (340). After breaches the endothelial basement membrane, T cells reach the perivascular space where they have to re-encounter their cognate antigen presented by antigen-presenting cells, in order to pursue their route into the neuropil (CNS parenchyma) (80). The final obstacle in this long journey is glia limitans composed of parenchymal basement membrane laid down by astrocytes (219). Activities of MMPs, especially MMP-2 and MMP-9, are essential for penetration of glia limitans (3).

After reaching the CNS parenchyma, astrocytes are the first cells encountered by leukocytes. Among many functions, astrocytes even take part in the regulation of leukocyte trafficking primarily by forming the scar-like barriers. These barriers serve to restrict leukocytes to perivascular clusters and limit their infiltration into adjacent CNS parenchyma, thus restricting the inflammatory process (326). The next step of leukocyte trafficking is contact with neurons that occurs through ICAM-5. This binding enables neurons to present T cells to neighboring glial cells and to help them induce T-cell apoptosis (309). Besides, neurons can induce proliferation of encephalitogenic T cells through up-regulation of TGF-β1 signaling pathway. Eventually, an interaction of neurons with T cells results in the conversion of encephalitogenic T cells into T-regulatory cells (Treg), which suppress encephalitogenic T cells showing bifunctional roles of neurons in the regulation of T-cell function and CNS inflammation (160).

Moreover, in vitro data indicate that astrocytes can prevent microglial cell cytotoxicity by mechanisms mediated by TGF/β1-Smad3 pathway in an age-dependent (310), suggesting that activation of the TGF/β1-Smad3 pathway is impaired in aging. If so, age-related impairment of TGF/β1-Smad3 could reduce protective activation and enhance cytotoxic activation of microglia, enhancing microglia and ROS-mediated age and stress-associated neurodegeneration.

Therefore, a multistep process of leukocytes crossing the BBB and a consequential reaction of neuronal and glial cells still need to be further clarified. Latest findings reveal that immune cell trafficking across the BBB appears to be independent on BBB integrity due to transcellular diapedesis stressing the relevance of the humoral components, mainly cytokine and ROS production which activates numerous signaling pathways in order to control the inflammation reaction.

IX. Concluding Remarks

The role of ROS as second messengers that control microglial dynamics is gaining increasing attention. Oxidant modifications on lipids and proteins reviewed here indicate the profound relevance that redox changes have in many cell types, and in microglia in particular, as well as in other aspects of neuroinflammation, including the integrity of the BBB and peripheral leukocyte infiltration. Transcription factor NF-κB has long been considered a master regulator of inflammation, but it is clear that transcription factor NRF2 is also closely associated with microglial activation. We have provided evidence that it is through maintenance of redox homeostasis that this protein opposes uncontrolled effects of ROS which might polarize microglia toward an exacerbated M1 pro-inflammatory phenotype. It is anticipated that, in the near future, the most prevalent diseases will be those affecting the elderly. Considering that ROS levels increase during aging and that ROS deregulate normal neuroinflammatory responses, we expect to see a growing interest in the redox pathophysiology of microglia-derived neuroinflammation which will uncover new drug targets to modulate the low-grade chronic neuroinflammation that characterizes neurodegenerative diseases.

Acknowledgments

This review was supported by the Spanish Ministry of Science and Innovation Refs. SAF2012-32222 (M.G.L.) and SAF2010-17822 (A.C.), the Spanish Ministry of Health (Instituto de Salud Carlos III) RETICS-RD06/0026 (M.G.L.), Pathfinder phase II of the Network of Centres of Excellence on Neurodegeneration (COEN) (A.C.), the Science Foundation, Ireland (G.M.) and the European Cooperation in Science and Research (COST Action BM1203/EU-ROS).

References


49. Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A, and Hayes JD. Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. *Oncogene* 32: 3765–3781, 2013.


Drechsel DA and Patel M. Respiration-dependent H2O2


Engelhardt B and Coisne C. Fluids and barriers of the CNS. Fluids Barriers CNS 8: 4, 2011.


133. Koppal T, Petrova TV, and Van Eldik LJ. Cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2)


162. Lovell MA, Xie C, and Markesbery WR. Acronein is increased in Alzheimer’s disease brain and is toxic to pri-


188. Medawar PB. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. *Br J Exp Pathol* 29: 58–69, 1948.


223. Pampliega O, Domercq M, Soria FN, Villolosa P, Rodriguez-Antigué A, and Matute C. Increased expres-


299. Sun Z, Huang Z, and Zhang DD. Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-dependent antioxidant response. PLoS One 4: e5688, 2009.


Address correspondence to:
Prof. Antonio Cuadrado
Institute of Biomedical Research “Alberto Sols”
UAM-CSIC and Department of Biochemistry
Faculty of Medicine
Autonomous University of Madrid (UAM)
C/Arturo Duperier 4
Madrid 28029
Spain

E-mail: antonio.cuadrado@uam.es

Dr. Ana I. Rojo
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)
C/Valderebollo 5
Madrid 28030
Spain

E-mail: airojo@iib.uam.es

Date of first submission to ARS Central, November 19, 2013; date of final revised submission, February 18, 2014; date of acceptance, March 5, 2014.

Abbreviations Used

$\beta$-TrCP = $\beta$-transducin repeat containing E3 ubiquitin protein ligase

6-OHDA = 6-hydroxydopamine

6PGD = phosphogluconate dehydrogenase

A$\beta$ = amyloid beta

AA = arachidonic acid

ACR = acrolein

AD = Alzheimer’s disease

ALS = amyotrophic lateral sclerosis

ARE = antioxidant response element

ARG1 = arginase-1

ASK1 = apoptosis-signal-regulating kinase 1

BBB = blood–brain barrier

Bcl2 = B-cell lymphoma-2

BH4 = tetrahydrobiopterin

BSO = buthionine-$S$-sulfoximine

CAT = cationic amino acid transporter

CCL-18 = chemokine 18

CD172a = receptor for CD47

CD200R1 = receptor for CD200

CG islands = cytosine guanine islands

CNS = central nervous system

COX2 = cyclooxygenase-2

CSF = cerebrospinal fluid

CXCR2 = receptor for CX3-chemokine ligand-1

DC-SIGN = dendritic cell-specific intracellular adhesion molecule 3-grabbing integrin

DHA = docosahexaenoic acid

DUOX = dual oxygenase

EAD = early stage Alzheimer’s disease

EAE = experimental autoimmune encephalomyelitis

EC = endothelial cell

ECM = extracellular matrix

ET = endotoxin tolerance

FIZZ1 = found in inflammatory zone

FT = ferritin

G6PDH = glucose-6-phosphate dehydrogenase

GCLC = glutamate-cysteine ligase catalytic subunit

GCLM = glutamate-cysteine ligase modulatory subunit

GLT-1 = glutamate transporter 1

GPx = glutathione peroxidase

GR, GSR = glutathione reductase

GSH = glutathione ($\gamma$-glutamyl-$\gamma$-cysteinylglycine)

GSK-3 = glycogen synthase kinase-3

GSSG = glutathione disulfide

GST = glutathione $S$-transferase

H$_2$O$_2$ = hydrogen peroxide

HDAC = histone deacetylase

HNE = 4-hydroxy-2-nonenal

*HO = hydroxyl radical

HO-1 = heme oxygenase-1

IBA-1 = ionized calcium-binding adapter molecule 1

ICAM-1 = intercellular adhesion molecule 1

IFN-$\gamma$ = interferon-$\gamma$

IL = interleukin

IL-12p40 = interleukin 12 p40 subunit

IL-1Ra = interleukin 1 receptor antagonist

IL-4Ra = interleukin 4 receptor $\alpha$

iNOS = inducible isoform of nitric oxide synthase

IsoPs = Isoprostanes
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>IκB</td>
<td>inhibitor of NF-κB</td>
</tr>
<tr>
<td>JNK</td>
<td>c-Jun N-terminal kinase</td>
</tr>
<tr>
<td>KEAPI</td>
<td>Kelch-like ECH-associated protein 1</td>
</tr>
<tr>
<td>LAD</td>
<td>late-stage Alzheimer’s disease</td>
</tr>
<tr>
<td>LCN2</td>
<td>lipocalin 2</td>
</tr>
<tr>
<td>LPS</td>
<td>lipopolysaccharide</td>
</tr>
<tr>
<td>LTP</td>
<td>long-term potentiation</td>
</tr>
<tr>
<td>MAPK</td>
<td>mitogen-activated protein kinase</td>
</tr>
<tr>
<td>MARCO</td>
<td>macrophage receptor with collagenous structure</td>
</tr>
<tr>
<td>MCI</td>
<td>mild cognitive impairment</td>
</tr>
<tr>
<td>MDA</td>
<td>malondialdehyde</td>
</tr>
<tr>
<td>MEKK</td>
<td>mitogen-activated protein kinase/ERK kinase</td>
</tr>
<tr>
<td>MHCII</td>
<td>major histocompatibility antigen II</td>
</tr>
<tr>
<td>MMP</td>
<td>matrix metalloproteinase</td>
</tr>
<tr>
<td>MPP⁺</td>
<td>1-methyl-4-phenylpyridinium</td>
</tr>
<tr>
<td>MPTP</td>
<td>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</td>
</tr>
<tr>
<td>MR</td>
<td>manose receptor</td>
</tr>
<tr>
<td>MS</td>
<td>multiple sclerosis</td>
</tr>
<tr>
<td>NAD(P)H</td>
<td>nicotinamide adenine dinucleotide phosphate</td>
</tr>
<tr>
<td>NeuroPs</td>
<td>neuroprostanes</td>
</tr>
<tr>
<td>NF-κB</td>
<td>nuclear factor kappa-light-chain-enhancer of activated B cells</td>
</tr>
<tr>
<td>NO</td>
<td>nitric oxide</td>
</tr>
<tr>
<td>NOS</td>
<td>nitric oxide synthase</td>
</tr>
<tr>
<td>nNOS</td>
<td>neuronal nitric oxide synthase</td>
</tr>
<tr>
<td>NOX</td>
<td>NADPH oxidase</td>
</tr>
<tr>
<td>NQO1</td>
<td>NAD(P)H:quinone oxidoreductase 1</td>
</tr>
<tr>
<td>NRF2</td>
<td>nuclear factor (erythroid-derived-2)-like 2</td>
</tr>
<tr>
<td>O₂⁻</td>
<td>superoxide anion</td>
</tr>
<tr>
<td>ONOO⁻</td>
<td>peroxynitrite</td>
</tr>
<tr>
<td>PD</td>
<td>Parkinson’s disease</td>
</tr>
<tr>
<td>PI3K</td>
<td>phosphatidylinositol-3 kinase</td>
</tr>
<tr>
<td>PKA</td>
<td>protein kinase A</td>
</tr>
<tr>
<td>PKC</td>
<td>protein kinase C</td>
</tr>
<tr>
<td>Prx</td>
<td>peroxiredoxin</td>
</tr>
<tr>
<td>RAGE</td>
<td>receptor for advanced glycation endproducts</td>
</tr>
<tr>
<td>RHD</td>
<td>Rel homology domain</td>
</tr>
<tr>
<td>RNS</td>
<td>reactive nitrogen species</td>
</tr>
<tr>
<td>ROS</td>
<td>reactive oxygen species</td>
</tr>
<tr>
<td>SFN</td>
<td>sulforaphane</td>
</tr>
<tr>
<td>SOCS</td>
<td>suppressors of cytokine signaling</td>
</tr>
<tr>
<td>SOCS3</td>
<td>suppressor of cytokine signaling 3</td>
</tr>
<tr>
<td>SOD</td>
<td>superoxide dismutase</td>
</tr>
<tr>
<td>SOD1</td>
<td>Cu/Zn-superoxide dismutase 1</td>
</tr>
<tr>
<td>sphk</td>
<td>sphingosine kinase</td>
</tr>
<tr>
<td>Srx</td>
<td>sulfiredoxin</td>
</tr>
<tr>
<td>TGF-β</td>
<td>transforming growth factor-β</td>
</tr>
<tr>
<td>TGF-b</td>
<td>tumor growth factor b</td>
</tr>
<tr>
<td>TJ</td>
<td>tight junctions</td>
</tr>
<tr>
<td>TLR</td>
<td>toll-like receptor</td>
</tr>
<tr>
<td>TNF</td>
<td>tumor necrosis factor</td>
</tr>
<tr>
<td>Trx</td>
<td>thioredoxin</td>
</tr>
<tr>
<td>TrxR</td>
<td>thioredoxin reductase</td>
</tr>
<tr>
<td>TXNIP</td>
<td>Trx-interacting protein</td>
</tr>
<tr>
<td>VCAM-1</td>
<td>vascular cell adhesion molecule 1</td>
</tr>
<tr>
<td>YM-1</td>
<td>mouse homolog chitinase 3 like 1 (CHI3L1)</td>
</tr>
<tr>
<td>γ-GCL</td>
<td>γ-glutamylcysteine synthetase</td>
</tr>
<tr>
<td>γGS</td>
<td>γ-glutamate cysteine synthetase</td>
</tr>
<tr>
<td>γGT</td>
<td>γ-glutamyl transpeptidase</td>
</tr>
</tbody>
</table>